<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Malignancy in inborn errors of immunity</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Malignancy in inborn errors of immunity</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Malignancy in inborn errors of immunity</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Payam Mohammadinejad, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Hassan Abolhassani, MD, PhD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Luigi D Notarangelo, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Anna M Feldweg, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Aug 02, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1067686845"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Patients with inborn errors of immunity (IEI), formerly called primary immunodeficiencies (PIDs), are at an increased risk of malignancy compared with the normal population [<a href="#rid1">1-3</a>]. After infections, malignancy is the second most common cause of death in these patients.</p><p>The epidemiology and etiology of common IEI-associated cancers, the most common types of cancer seen in patients with different forms of IEI, monitoring of patients with IEI for malignancies, and issues surrounding cancer treatment will be reviewed here. An overview of the medical management of immunodeficiency and a discussion of the pulmonary complications of IEI are found separately. (See  <a class="medical medical_review" href="/z/d/html/3948.html" rel="external">"Inborn errors of immunity (primary immunodeficiencies): Overview of management"</a> and  <a class="medical medical_review" href="/z/d/html/15830.html" rel="external">"Pulmonary complications of primary immunodeficiencies"</a> and  <a class="medical medical_review" href="/z/d/html/99315.html" rel="external">"Gastrointestinal manifestations in primary immunodeficiency"</a>.)</p><p class="headingAnchor" id="H1067686851"><span class="h1">EPIDEMIOLOGY AND PREVALENCE OF CANCER IN IEI</span><span class="headingEndMark"> — </span>The overall risk for developing cancer in patients with IEI is increased less than two-fold above that of the general population, and has been estimated to range from 4 to 25 percent [<a href="#rid4">4,5</a>]. Advances in the therapeutic management of IEI, most notably <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">immune globulin</a> replacement therapy, have resulted in a longer life expectancy and duration of disease [<a href="#rid1">1</a>]. As patients with IEI live longer, malignancies are diagnosed more commonly. A few studies have examined the increased risk of malignancy in patients with IEI:</p><p class="bulletIndent1"><span class="glyph">●</span>The largest study included 3658 IEI patients enrolled in the United States Immune Deficiency Network (USIDNET) Registry between 2003 and 2015, among which approximately 5 percent of patients reported cancers. There was a 1.42-fold excess relative risk compared with the age-adjusted population surveyed in the Surveillance, Epidemiology, and End Results (SEER), which is a population-based registry for cancer in the United States [<a href="#rid5">5</a>]. Male patients with IEI had a 1.91-fold excess relative risk of cancer compared with the age-adjusted male SEER population. In contrast, female IEI patients had similar cancer rates compared with their age-adjusted counterparts in the population. There was also a 10-fold increase for lymphoma in male IEI patients and an 8.34-fold increase for female IEI patients. There was no significant difference in the rates of common malignancies (ie, lung, colon, breast, and prostate) in patients with IEI compared with the control population.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>An earlier study by the Australasian Society of Clinical Immunology and Allergy (ASCIA) calculated the standardized incidence ratio (SIR) of malignancy in 1132 IEI patients [<a href="#rid6">6</a>]. SIRs were significantly elevated for all cancers (combined SIR 1.60), cancer of the thymus gland (SIR 67.3), non-Hodgkin lymphoma (NHL) (SIR 8.82), stomach cancer (SIR 6.10), and leukemia (SIR 5.36). "All cancer" and site-specific SIRs were not different for men and women, except for thymoma, which was only identified in men [<a href="#rid6">6</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a study of 745 patients with IEI reported in the Netherlands between 2009 and 2012, almost 10 percent of the patients suffered from a malignancy. Compared with the general Dutch population, the relative risk of developing any malignancy was two- to threefold higher, with a &gt;10-fold increase for some solid (eg, thyroid, thymus) and hematologic tumors (eg, leukemia, lymphoma) [<a href="#rid7">7</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a study of 1318 patients with IEI studied in the UK National Institute for Health Research and BioResource–Rare Diseases programme, 8 percent had malignancy with a predominant clinical diagnosis of antibody deficiencies [<a href="#rid8">8</a>]. Patients with combined immunodeficiency (13 percent), phagocyte disorders (13 percent), and severe autoimmunity (12 percent) showed a higher risk of malignancy relative to others. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A 2019 systematic review of 456 patients with IEI and malignancy reported unspecified NHL (37 percent), diffuse large B cell lymphoma (DLBCL, 15 percent), and Hodgkin lymphoma (HL, 13 percent), with similar rates in males and females [<a href="#rid9">9</a>]. Antibody deficiency and DNA repair disorders (mainly NBS and AT deficiencies) were the most frequently reported disorders. T cell lymphomas were reported in 74 patients, mostly males. </p><p></p><p class="headingAnchor" id="H18870685"><span class="h2">Most common types of cancer</span><span class="headingEndMark"> — </span>According to the Immunodeficiency Cancer Registry database on immunodeficiency-associated cancer at the University of Minnesota, the most common types of malignancies among IEI patients are NHL and Hodgkin lymphoma, which account for 48.6 and 10 percent of cancers seen in IEI patients, respectively [<a href="#rid10">10</a>]. In the USIDNET study, lymphomas were again the most common and accounted for 48 percent of all cancers observed in IEI patients (mainly in patients with common variable immunodeficiency [CVID]), followed by skin cancer (15 percent), and gastrointestinal and genitourinary cancers (each 8 percent) [<a href="#rid5">5</a>]. NHL represented 28 percent of all identified cancers in the ASCIA study [<a href="#rid6">6</a>]. The most common type of NHL in IEI patients is diffuse large B cell lymphoma [<a href="#rid11">11</a>]. A table summarizing the cancers most commonly seen in patients with different types of IEI is provided  (<a class="graphic graphic_table graphicRef96198" href="/z/d/graphic/96198.html" rel="external">table 1</a>).</p><p>Both NHL and Hodgkin lymphoma are diagnosed at younger ages in patients with IEI, and NHL is more common in males with IEI [<a href="#rid12">12-14</a>]. In a study of 1413 patients with NHL, of whom 19 had IEI, the median age of the patients at the time of diagnosis was significantly lower among IEI patients compared with immunocompetent individuals (7.8 years versus 9.3 years) [<a href="#rid12">12</a>]. Similarly, in a case-control study of 120 pediatric Hodgkin lymphoma patients consisting of 20 IEI and 100 immunocompetent individuals, the mean age of the patients at the time of diagnosis was 7.8 years and 11.5 years, respectively [<a href="#rid15">15</a>]. Surprisingly, tumors that are known to use mechanisms to escape immune detection, such as melanoma and renal cell carcinoma, do not appear to be prevalent in IEI [<a href="#rid16">16</a>].</p><p class="headingAnchor" id="H18870695"><span class="h2">Disorders with higher cancer incidence</span><span class="headingEndMark"> — </span>The majority of IEI-related cancers are associated with two specific IEI disorders: ataxia-telangiectasia and CVID, which account for 30 and 24 percent of malignancy among IEI patients, respectively [<a href="#rid13">13</a>]. Another one-third of cases are reported in association with Wiskott-Aldrich syndrome, severe combined immunodeficiency, and selective immunoglobulin (Ig)A deficiency.</p><p class="headingAnchor" id="H1067686863"><span class="h1">MECHANISMS OF INCREASED SUSCEPTIBILITY TO MALIGNANCY</span><span class="headingEndMark"> — </span>The exact pathophysiology of cancer is not fully determined in many IEI cases, although several mechanisms have been suggested to contribute to the high susceptibility of distinct groups of patients to specific types of malignancies [<a href="#rid17">17</a>]. These include intrinsic factors associated mainly with hematologic cancers (eg, impaired genetic stability, genetic predisposition, and impaired immune function) and extrinsic factors associated mainly with carcinomas (eg, impaired clearance of oncogenic viruses, chronic tissue inflammation, and iatrogenic causes) [<a href="#rid16">16</a>]. These oncogenic factors might synergize with or even depend upon each other. The fourth column of the table lists mechanisms of malignant transformation in various IEI disorders  (<a class="graphic graphic_table graphicRef96198" href="/z/d/graphic/96198.html" rel="external">table 1</a>).</p><p class="headingAnchor" id="H1067686869"><span class="h2">Impaired genetic stability</span><span class="headingEndMark"> — </span>One of the better-understood mechanisms is impaired genetic stability caused by defective DNA repair [<a href="#rid1">1</a>]. Ataxia-telangiectasia (AT) and Nijmegen breakage syndrome (NBS) are the best known examples of IEI involving defective DNA repair [<a href="#rid18">18</a>]. This mechanism may also contribute to the development of malignant cells in patients with Wiskott-Aldrich syndrome (WAS) and epidermodysplasia verruciformis (EV). Defects of chromosome stability and DNA repair predispose selected patients with severe combined immunodeficiency (with mutations in nonhomologous end-joining), ICF syndrome (or <strong>i</strong>mmunodeficiency, <strong>c</strong>entromere instability and <strong>f</strong>acial anomalies syndrome), dyskeratosis congenital, Bloom syndrome, and class-switching recombination defects to a higher risk of lymphoma, leukemia, and carcinoma [<a href="#rid16">16</a>].</p><p class="headingAnchor" id="H1067686875"><span class="h3">Ataxia-telangiectasia</span><span class="headingEndMark"> — </span>Ataxia-telangiectasia (AT) is an autosomal recessive disorder caused by a defect in the AT mutated (<em>ATM</em>) gene resulting in impaired DNA repair [<a href="#rid19">19</a>]. AT is clinically characterized by recurrent infections due to defective cellular and humoral immune response, neurologic complications in the form of ataxia, and high susceptibility to malignancy, as well as increased radiosensitivity [<a href="#rid20">20</a>]. In a study of the French national registry of IEI, among 279 patients with AT, 69 (24.5 percent) were diagnosed with cancer, with non-Hodgkin lymphoma (NHL), Hodgkin lymphoma, and T cell acute lymphoblastic leukemia being the most common [<a href="#rid21">21</a>]. (See  <a class="medical medical_review" href="/z/d/html/6233.html" rel="external">"Ataxia-telangiectasia"</a>.)</p><p>The ATM protein plays an essential role in regulation of the cell cycle checkpoints and phosphorylation of p53 protein, a product of the <em>TP53</em> tumor suppressor gene, which promotes cell cycle arrest and apoptosis in cells with damaged DNA [<a href="#rid22">22-25</a>]. Functional products of the <em>ATM</em> gene are also essential in the phosphorylation of the breast cancer susceptibility gene 1 tumor suppressor protein [<a href="#rid25">25</a>]. Accordingly, patients with biallelic mutations and individuals with heterozygous mutant <em>ATM</em> genes are reported to be at increased risk of breast cancer [<a href="#rid26">26-28</a>]. There has also been some evidence in support of a possible increase in the risk of gastrointestinal malignancies in individuals with heterozygous mutations in <em>ATM</em>. However, the relationship does not seem to be as strong as that with breast cancer [<a href="#rid29">29</a>]. (See  <a class="medical medical_review" href="/z/d/html/792.html" rel="external">"Factors that modify breast cancer risk in women", section on 'Personal and family history of breast cancer'</a>.)</p><p class="headingAnchor" id="H1067686881"><span class="h3">Nijmegen breakage syndrome</span><span class="headingEndMark"> — </span>Nijmegen breakage syndrome (NBS) is a rare, autosomal recessive disorder caused by a defective <em>NBS</em> gene, also known as <em>NBN</em>, <em>NBS1</em>, and <em>P95</em> gene, resulting in an impaired DNA repair, similar to AT [<a href="#rid1">1</a>]. NBS is clinically characterized by recurrent infections due to a defective cellular and humoral immune response, neurologic complications in the form of microcephaly, and high susceptibility to malignancy, including lymphoma and acute leukemia [<a href="#rid30">30</a>]. (See  <a class="medical medical_review" href="/z/d/html/3957.html" rel="external">"Nijmegen breakage syndrome"</a>.)</p><p>The <em>NBS</em> gene product is considered a component of the same pathway as the ATM protein. The <em>NBS</em> gene directs the production of nibrin protein [<a href="#rid31">31</a>]. Nibrin phosphorylation is promoted by ATM [<a href="#rid32">32,33</a>]. Phosphorylated nibrin is considered a catalyst for phosphorylation of other molecules involved in the cell cycle, including checkpoint kinase 2, checkpoint kinase 1, and structural maintenance of chromosome 1 [<a href="#rid34">34,35</a>]. Moreover, nibrin itself forms a complex with products of <em>MRE11</em> and <em>RAD50</em> genes, known as MRN complex (Mre11-Rad50-Nbs1 complex), which is an essential component of ATM-mediated response to DNA damage [<a href="#rid36">36</a>]. Hence, the <em>NBS</em> gene has roles in both upstream and downstream of DNA damage response regulated by the <em>ATM</em> gene [<a href="#rid31">31</a>].</p><p class="headingAnchor" id="H1067686893"><span class="h3">Wiskott-Aldrich syndrome</span><span class="headingEndMark"> — </span>Wiskott-Aldrich syndrome (WAS) is a combined immunodeficiency with an X-linked pattern of inheritance caused by mutations in gene-encoding WAS protein (WASP), which acts as a key regulator of cell signaling and reorganization of cytoskeleton in hematopoietic cells [<a href="#rid37">37</a>]. WAS is clinically characterized by thrombocytopenia, eczema, immunodeficiency, autoimmune manifestations, and increased susceptibility to malignancy [<a href="#rid38">38</a>]. Although some authors have suggested that WASP may play a direct role in genomic stability, genetic instability is not considered to be the main reason for the development of malignancies in WAS patients [<a href="#rid39">39,40</a>]. (See  <a class="medical medical_review" href="/z/d/html/3953.html" rel="external">"Wiskott-Aldrich syndrome"</a>.)</p><p>The incidence of malignancy in WAS patients ranges between 13 and 22 percent, with a 9 percent incidence of lymphoma [<a href="#rid39">39,41</a>]. Leukemia and lymphoma are most commonly observed in adolescents and young adults. Epstein-Barr virus (EBV)-related B cell lymphoma is the most common malignancy [<a href="#rid42">42,43</a>]. Other malignancies, including cerebellar astrocytoma, Kaposi sarcoma, or rarely, smooth muscle tumors, have also been reported [<a href="#rid44">44-46</a>].</p><p class="headingAnchor" id="H1067686912"><span class="h3">Epidermodysplasia verruciformis</span><span class="headingEndMark"> — </span>Epidermodysplasia verruciformis (EV) is a rare disorder that is clinically characterized by a high susceptibility to specific genotypes of cutaneous human papillomavirus (HPV) and squamous cell carcinoma [<a href="#rid38">38</a>]. Manifestations of EV begin during infancy or childhood and include tinea versicolor-like macules and flat wart-like papules. These cutaneous lesions may undergo malignant transformation to in situ or invasive squamous cell carcinoma, especially in sun-exposed areas [<a href="#rid47">47</a>]. In the majority of the cases, the disease is inherited as an autosomal recessive trait, due to mutations of the <em>EVER1</em> or <em>EVER2</em> genes [<a href="#rid48">48</a>].</p><p>Genetic instability due to a defective DNA repair is observed in EV patients [<a href="#rid17">17,49</a>]. E6 oncoprotein produced by EV-associated HPVs (EV-HPVs) inhibits the proapoptotic role of B cell lymphoma 2 (Bcl-2) protein in ultraviolet light-induced apoptosis [<a href="#rid50">50</a>]. In addition, the E6 protein produced by HPV-8 may directly cause genetic instability by binding to x-ray repair cross-complementing protein 1 (XRCC1), a crucial protein needed in DNA repair [<a href="#rid51">51</a>]. This EV-HPV-induced genetic instability is known to be responsible in the early stages of malignant formation of cutaneous cells in EV patients [<a href="#rid52">52,53</a>]. Impaired function of the immune system is also believed to contribute to malignancy in this disorder. (See <a class="local">'Epidermodysplasia verruciformis'</a> below.)</p><p class="headingAnchor" id="H1067686918"><span class="h2">Genetic predisposition</span><span class="headingEndMark"> — </span>A genetic predisposition to specific types of malignancies is a probable etiology of cancer in a number of IEI patients, although not usually as a result of oncogenic genes. Instead, other mechanisms appear to be important, such as the presence of certain mutations in genes associated with leukocyte development or defective tumor suppression genes.</p><p class="headingAnchor" id="H1828553921"><span class="h3">Leukocyte development defects</span><span class="headingEndMark"> — </span>Multipotential self-renewing hematopoietic cells (&lt;0.1 percent of the bone marrow cells) develop continuously to both myeloid and lymphoid lineages. As stem cell differentiation progresses, there is an advanced commitment to a given lineage due to regulation of a specific group of genes, which defects in those can manifest as severe congenital neutropenia (SCN) and other bone marrow failure syndromes.</p><p class="headingAnchor" id="H1067686924"><span class="h4">Severe congenital neutropenia</span><span class="headingEndMark"> — </span>Severe congenital neutropenia (SCN) is a IEI caused by impaired myelopoiesis, resulting in neutropenia. SCN is clinically characterized by a tendency to recurrent and severe infections and a high prevalence of leukemia [<a href="#rid54">54</a>]. Autosomal dominant, autosomal recessive, and X-linked patterns of inheritance are reported [<a href="#rid54">54</a>]. (See  <a class="medical medical_review" href="/z/d/html/8373.html" rel="external">"Congenital neutropenia"</a>.)</p><p>In a long-term survey on the incidence of leukemia among SCN patients, mutations in the gene for granulocyte colony-stimulating factor (G-CSF) receptor (<em>CSF3R</em>) were observed in 78 percent of patients with a diagnosed malignancy [<a href="#rid55">55</a>]. Although these mutations are not essential in the formation of leukemia in SCN patients, mutations in <em>CSF3R</em> are considered a predisposing factor for malignant transformation. Moreover, high-dose treatment and overstimulation with G-CSF may increase the risk of malignancy in SCN patients [<a href="#rid56">56</a>]. (See  <a class="medical medical_review" href="/z/d/html/8373.html" rel="external">"Congenital neutropenia", section on 'Treatment'</a>.)</p><p class="headingAnchor" id="H2691405288"><span class="h4">Bone marrow failure syndromes</span><span class="headingEndMark"> — </span>Shwachman-Diamond syndrome, cartilage-hair hypoplasia, and other immuno-osseous dysplasias may present with short stature, myelodysplasia, bone marrow failure, susceptibility to lymphoma, and leukemia [<a href="#rid57">57</a>]. (See  <a class="medical medical_review" href="/z/d/html/5914.html" rel="external">"Shwachman-Diamond syndrome"</a> and  <a class="medical medical_review" href="/z/d/html/3916.html" rel="external">"Cartilage-hair hypoplasia"</a>.)</p><p class="headingAnchor" id="H1067686930"><span class="h3">Defective tumor suppression genes</span><span class="headingEndMark"> — </span>Tumor suppressor genes encode for proteins that are involved in inhibiting the proliferation of immune cells and controlling the inflammatory process, which is crucial to normal cell development and differentiation of both innate and adaptive immunities. Patients with mutations in these genes, including dedicator of cytokinesis 8 (DOCK) deficiency, common variable immunodeficiency (CVID), autoimmune lymphoproliferative syndrome (ALPS), and other chronic inflammatory disorders, are at a higher predisposition to malignancy.</p><p class="headingAnchor" id="H956852682"><span class="h4">DOCK8 deficiency</span><span class="headingEndMark"> — </span>Dedicator of cytokinesis 8 (DOCK8) deficiency is a combined immunodeficiency with an autosomal recessive pattern of inheritance [<a href="#rid58">58</a>]. DOCK8 deficiency is characterized by recurrent respiratory tract infections, widespread cutaneous viral infections, atopy, and malignancy (vulvar, facial, and anal squamous cell dysplasia and carcinomas, and T cell lymphoma-leukemia) [<a href="#rid59">59</a>]. It was categorized previously as a subgroup of hyperimmunoglobulin E syndrome, due to similar clinical features [<a href="#rid60">60</a>]. (See  <a class="medical medical_review" href="/z/d/html/3960.html" rel="external">"Autosomal dominant hyperimmunoglobulin E syndrome", section on 'Dedicator of cytokinesis 8 and tyrosine kinase 2 deficiencies'</a> and  <a class="medical medical_review" href="/z/d/html/141326.html" rel="external">"Combined immunodeficiencies: Specific defects", section on 'DOCK8 deficiency'</a>.)</p><p>Although the exact etiology of malignant transformation in DOCK8-deficient patients is not clearly understood, it is suggested that DOCK8 protein may play a direct tumor suppressor role, which is lost in these individuals [<a href="#rid61">61</a>]. This theory is supported by the observation of decreased expression of the DOCK8 protein in cell lines of patients with lung cancer and soft tissue sarcomas [<a href="#rid62">62,63</a>].</p><p class="headingAnchor" id="H956852698"><span class="h4">Common variable immunodeficiency</span><span class="headingEndMark"> — </span>Common variable immunodeficiency (CVID) is a heterogeneous group of disorders caused by impairments in B cell differentiation, resulting in defective immunoglobulin production. CVID is clinically characterized by recurrent infections, especially of the upper and lower respiratory tract, autoimmune manifestations, gastrointestinal complications, and increased susceptibility to malignancies. Although several genetic mutations have been reported in CVID patients, the molecular basis of this disorder is not known in most cases, and knowledge about the process of malignant formation in these individuals is limited [<a href="#rid64">64,65</a>]. However, impaired immunity to herpes viruses, chronic inflammation, and DNA repair defects are known predisposing factors in this group of patients [<a href="#rid66">66</a>]. (See  <a class="medical medical_review" href="/z/d/html/3928.html" rel="external">"Clinical manifestations, epidemiology, and diagnosis of common variable immunodeficiency in adults"</a> and  <a class="medical medical_review" href="/z/d/html/3904.html" rel="external">"Pathogenesis of common variable immunodeficiency"</a> and  <a class="medical medical_review" href="/z/d/html/3952.html" rel="external">"Treatment and prognosis of common variable immunodeficiency"</a> and  <a class="medical medical_review" href="/z/d/html/16132.html" rel="external">"Common variable immunodeficiency in children"</a>.)</p><p>The incidence of malignancy among CVID patients has been estimated to be around 10 percent, ranging from 1.5 to 20.7 percent in different studies [<a href="#rid67">67</a>]. This incidence was reported to be about three to four times higher when CVID is diagnosed in adulthood, compared with when the onset of symptoms is before the age of 16 years [<a href="#rid2">2</a>]. In the Australasian Society of Clinical Immunology and Allergy study, a 7-fold increase in the risk of stomach cancer, a 12-fold increase in NHL risk, and a 146-fold increase in thymus cancer were identified [<a href="#rid6">6</a>]. Lymphoma decreased the survival rate of CVID patients compared with age- and sex-matched controls [<a href="#rid68">68</a>]. The mechanisms of increased susceptibility to NHL and thymus cancer have not been elucidated. Although hematopoietic cell transplantation (HCT) is not usually indicated in CVID patients due to poor outcome, the survival rate for patients undergoing transplantation with reduced-intensity conditioning regimens for lymphoma was 83 percent, and these patients tended to have a more favorable comorbidity score [<a href="#rid69">69</a>].</p><p>Altered function of P53 protein produced by the <em>TP53</em> tumor suppressor gene is considered to be associated with gastric malignancies in patients with CVID [<a href="#rid70">70</a>]. However, several other factors, including chronic <em>Helicobacter pylori</em> infection, pernicious anemia, achlorhydria, and decreased gastric IgA secretion may also predispose these patients to the development of gastric malignancies [<a href="#rid6">6</a>]. Of note, long-term follow-up of IgA-deficient individuals, a milder form of antibody deficiency compared with CVID, showed a moderately increased risk of gastrointestinal cancer [<a href="#rid71">71</a>].</p><p class="headingAnchor" id="H2460760451"><span class="h4">Autoimmune lymphoproliferative syndrome</span><span class="headingEndMark"> — </span>Autoimmune lymphoproliferative syndrome (ALPS) is characterized by dysregulation of the immune system due to an inability to regulate lymphocyte homeostasis through the process of lymphocyte apoptosis (a form of programmed cell death). Impaired lymphocyte differentiation and senescence results and patients with ALPS have a higher risk of lymphoma [<a href="#rid72">72</a>]. (See  <a class="medical medical_review" href="/z/d/html/16361.html" rel="external">"Autoimmune lymphoproliferative syndrome (ALPS): Epidemiology and pathogenesis"</a>.)</p><p></p><p class="headingAnchor" id="H775598810"><span class="h4">Other IEI disorders with chronic tissue inflammation</span><span class="headingEndMark"> — </span>Chronic mucocutaneous candidiasis is often accompanied by extensive inflammatory disorders, predisposing patients mainly to carcinoma. Careful oral hygiene is important for these patients, and aggressive treatment of oral and oesophageal candidiasis, as well as routine endoscopic screening for esophageal cancer, are recommended [<a href="#rid73">73</a>]. (See  <a class="medical medical_review" href="/z/d/html/13569.html" rel="external">"Chronic mucocutaneous candidiasis", section on 'Treatment'</a>.)</p><p>Another example of a IEI disorder involving chronic tissue inflammation is immune dysregulation with colitis due to mutations in interleukin (IL)-10 receptor genes (<em>IL10RA</em> and <em>IL10RB</em>), which may carry an increased risk of lymphoma [<a href="#rid74">74</a>]. (See  <a class="medical medical_review" href="/z/d/html/5904.html" rel="external">"Lower gastrointestinal bleeding in children: Causes and diagnostic approach", section on 'Infantile and very early-onset inflammatory bowel disease'</a>.)</p><p class="headingAnchor" id="H1067686937"><span class="h2">Impaired function of immune system</span><span class="headingEndMark"> — </span>The immune system plays a critical role in the surveillance of oncogenic pathogens, as well as premalignant and malignant cells. Impaired immune response results in decreased viral clearance, chronic antigen stimulation, chronic inflammatory response, and survival and proliferation of premalignant and malignant cells, all of which can predispose these patients to oncogenic mutations and malignant transformation [<a href="#rid75">75-77</a>].</p><p></p><p class="headingAnchor" id="H1067686943"><span class="h3">X-linked lymphoproliferative disease</span><span class="headingEndMark"> — </span>X-linked lymphoproliferative disease (XLP), also known as Duncan disease, is caused by mutations in the signaling lymphocytic activation molecule (SLAM)-associated protein (<em>SAP</em>) gene [<a href="#rid78">78,79</a>]. XLP is clinically characterized by excessive susceptibility to EBV infection, resulting in fulminant infectious mononucleosis, dysgammaglobulinemia, and lymphoma [<a href="#rid80">80</a>]. There is another form of the disorder (XLP2) that is not known to be associated with increased susceptibility to malignancy. (See  <a class="medical medical_review" href="/z/d/html/3915.html" rel="external">"X-linked lymphoproliferative disease"</a>.)</p><p><em>SAP</em> expression has been observed in thymocytes, T cells, natural killer (NK) cells, invariant natural killer T (iNKT) cells, and possibly in a subgroup of B cells [<a href="#rid81">81,82</a>]. <em>SAP</em> is known to facilitate the interaction between T cells and antigen-presenting cells, as well as between NK cells and target cells [<a href="#rid83">83</a>]. Additionally, absence of iNKT cells has been reported among <em>SAP</em>-deficient patients [<a href="#rid17">17,84</a>]. Loss of cytotoxic function of T and NK cells may result in the survival of EBV-transformed B cells in these patients [<a href="#rid85">85,86</a>]. <em>SAP</em> is also known to promote an apoptotic response to DNA damage among malignant T and B lymphocyte-derived cell lines, which may explain the dysregulated activation and expansion of T cells, as well as the persistence of premalignant B cells, even in the absence of EBV infection [<a href="#rid87">87</a>].</p><p class="headingAnchor" id="H1067686949"><span class="h3">ITK deficiency</span><span class="headingEndMark"> — </span>IL-2-inducible T cell kinase (ITK) deficiency is a rare form of EBV-associated lymphoproliferative disease caused by mutations in the <em>ITK</em> gene, also known as IL-2-inducible T cell kinase and tyrosine-protein kinase (<em>ITK/TSK</em>) gene, with a similar clinical presentation to XLP. ITK deficiency is clinically characterized by EBV-induced immune dysregulation and susceptibility to Hodgkin lymphoma [<a href="#rid88">88,89</a>].</p><p>ITK expression has been observed in thymocytes, mature T cells, NK cells, iNKT cells, and mast cells [<a href="#rid89">89,90</a>]. ITK is believed to play a modulatory role in the signaling cascade of T cell receptors, which results in the cytotoxic function of T cells [<a href="#rid89">89,91</a>]. In addition, a significant decrease in the number of iNKT cells has been reported in ITK-deficient patients [<a href="#rid88">88</a>]. Hence, an impaired cytotoxic response may predispose these patients to infections by oncogenic viruses, such as EBV. On the other hand, a reported impaired NK cell-mediated cytotoxicity due to ITK deficiency may be responsible for the survival of premalignant or malignant cells [<a href="#rid92">92</a>].</p><p class="headingAnchor" id="H1067686961"><span class="h3">Epidermodysplasia verruciformis</span><span class="headingEndMark"> — </span>Impaired function of the immune system may also be involved in the high prevalence of cutaneous malignancies among epidermodysplasia verruciformis (EV) patients. Mutations in <em>EVER1</em> and <em>EVER2</em> genes have been reported in up to 75 percent of EV patients [<a href="#rid93">93</a>]. The expression of EVER proteins has been observed in T, B, NK, and dendritic cells, indicating their probable role in the impaired immune response against HPV, as well as survival of premalignant cells in EV patients [<a href="#rid94">94</a>].</p><p class="headingAnchor" id="H1067686967"><span class="h3">Wiskott-Aldrich syndrome</span><span class="headingEndMark"> — </span>Impaired function of the immune system may also be partially responsible for tumor development in Wiskott-Aldrich syndrome (WAS) patients. There is some evidence that defects in the function of NK cells, as well as other components of the human immune system, may result in malignant formation due to defective tumor surveillance [<a href="#rid1">1,43</a>]. (See  <a class="medical medical_review" href="/z/d/html/3953.html" rel="external">"Wiskott-Aldrich syndrome"</a>.)</p><p class="headingAnchor" id="H3153392335"><span class="h3">CD40 ligand deficiency</span><span class="headingEndMark"> — </span>CD40 ligand (CD40L) is a molecule expressed by CD4+ T cells upon activation and interacts with CD40, expressed by multiple cell types, including B cells, dendritic cells, monocytes, and some endothelial and epithelial cells. Mutations in the <em>CD40L</em> gene cause X-linked immunodeficiency with hyperimmunoglobulin M. These patients are highly prone to biliary tract infections sustained by <em>Cryptosporidium</em> and by cytomegalovirus and are at increased risk of cholangiocarcinoma and peripheral neuroectodermal tumors of the gastrointestinal tract [<a href="#rid95">95</a>]. Other genetic causes of hyperimmunoglobulin M, including mutations in the gene for the postmeiotic segregation increased 2 protein (<em>PMS2</em>), can be associated with lymphoma due to impaired function of the immune system and genetic instability [<a href="#rid96">96</a>].  </p><p class="headingAnchor" id="H1741134068"><span class="h3">Natural killer cell deficiency</span><span class="headingEndMark"> — </span>Natural killer (NK) cells have diverse functions for contact and antibody-dependent killing of cancerous cells and serve as the main member of innate immune defense against malignancies. Therefore, patients with genetically defined congenital immunodeficiency in low-affinity immunoglobulin Fc-gamma-receptor IIIA (<em>FCGR3A</em>) and minichromosome maintenance complex component 4 (<em>MCM4</em>) genes mutation are more susceptible to carcinoma [<a href="#rid97">97,98</a>]. (See  <a class="medical medical_review" href="/z/d/html/3949.html" rel="external">"NK cell deficiency syndromes: Clinical manifestations and diagnosis"</a>.) </p><p class="headingAnchor" id="H1067686979"><span class="h2">Decreased viral clearance</span><span class="headingEndMark"> — </span>Oncogenic viruses may play a role in the malignant transformation in about 10 to 15 percent of malignancies in the general population [<a href="#rid75">75</a>]. Since immune dysregulation is the main feature of IEI disorders, it is not surprising that decreased viral clearance is one of the main etiologies for an increased prevalence of malignancies among these patients. In IEI patients, infection with these viruses can lead to a persistent inflammatory response, ongoing cell proliferation, and abnormal cell survival, all of which may increase the chance that an oncogenic mutation arises [<a href="#rid76">76</a>].</p><p class="headingAnchor" id="H1067686985"><span class="h3">Epstein-Barr virus</span><span class="headingEndMark"> — </span>Epstein-Barr virus (EBV) is the best-studied virus responsible for malignant transformation in IEI disorders [<a href="#rid17">17</a>]. EBV is transmitted via person-to-person oral or sexual contact, blood transfusion, or tissue transplantation [<a href="#rid99">99</a>]. (See  <a class="medical medical_review" href="/z/d/html/8318.html" rel="external">"Infectious mononucleosis", section on 'Transmission'</a>.)</p><p>EBV infection involves lymphocytes, especially B cells, which act as a reservoir for the virus. As a result, lymphomas of B cell origin are the most common malignancy linked to EBV infections [<a href="#rid99">99</a>]. EBV infection triggers an initial immune response consisting of B cell proliferation and secretion of both specific and nonspecific antibodies against EBV. In a person with an intact immune system, cellular immunity as provided by T cell cytotoxicity and other components of the immune system follows this process, limiting the primary infection. The inability to suppress the EBV and keep the infection in a latent state is believed responsible for several B cell lymphoproliferative disorders (BLPDs), including Hodgkin lymphoma, Burkitt lymphoma, and post-transplant lymphoproliferative disorders (PTLDs) in patients with IEI [<a href="#rid17">17</a>]. </p><p>EBV infection is associated with BLPDs in:</p><p class="bulletIndent1"><span class="glyph">●</span>Severe combined immunodeficiencies (eg, adenosine deaminase [ADA] deficiency [<a href="#rid96">96</a>], coronin 1A [CORO1A] deficiency [<a href="#rid100">100</a>]) (see  <a class="medical medical_review" href="/z/d/html/3912.html" rel="external">"Severe combined immunodeficiency (SCID): Specific defects", section on 'Adenosine deaminase deficiency'</a> and  <a class="medical medical_review" href="/z/d/html/3912.html" rel="external">"Severe combined immunodeficiency (SCID): Specific defects", section on 'Actin-regulating protein coronin 1A deficiency'</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Combined immunodeficiencies (eg, interleukin 2-inducible T cell kinase [ITK] deficiency [<a href="#rid101">101</a>]) (see <a class="local">'ITK deficiency'</a> above)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Syndromic combined immunodeficiencies (eg, Wiskott-Aldrich syndrome [WAS])</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Diseases of immune dysregulation (eg, X-linked lymphoproliferative syndrome [XLP], cytidine 5' triphosphate synthase 1 [CTPS1] deficiency [<a href="#rid102">102</a>], and X-linked immunodeficiency with magnesium defect, EBV infection, and neoplasia [XMEN]) (See  <a class="medical medical_review" href="/z/d/html/3915.html" rel="external">"X-linked lymphoproliferative disease"</a> and <a class="local">'XMEN disease'</a> below and <a class="local">'CTP synthase 1 deficiency'</a> below.)</p><p></p><p class="headingAnchor" id="H847302452"><span class="h4">XMEN disease</span><span class="headingEndMark"> — </span>X-linked immunodeficiency with magnesium defect, EBV infection, and neoplasia (XMEN) is a IEI disorder caused by a loss-of-function mutation of the gene encoding magnesium transporter 1 (<em>MAGT-1</em>) [<a href="#rid103">103-105</a>]. It is characterized by chronic EBV infection, splenomegaly, elevated EBV-infected B cells, reversed CD4:CD8 ratio, and unusual susceptibility to EBV-associated lymphomas. The small number of patients reported have also suffered from frequent sinopulmonary infections, epiglottitis, and diarrhea. They have been developmentally normal.</p><p class="headingAnchor" id="H3531204314"><span class="h4">CTP synthase 1 deficiency</span><span class="headingEndMark"> — </span>Synthesis of cytidine 5' triphosphate (CTP), which is required for the metabolism of DNA, RNA, and phospholipid, involves two enzymes, CTP synthase 1 and 2 (CTPS1 and CTPS2). CTPS1 is required for proliferation, but not differentiation, of T cells in response to TCR-CD3 activation by antigens. Proliferation of B cells is also dependent upon CPTS1.</p><p>Several patients have been identified with a homozygous mutation in <em>CTPS1</em> that ablates protein expression [<a href="#rid102">102</a>]. Symptoms begin in infancy to early childhood. All patients reported have had severe chronic viral infections and recurrent encapsulated bacterial infections. Two patients had non-Hodgkin lymphoma associated with EBV infection. Three of the eight patients reported in this series had died, and six had undergone HCT. No patients had extra-hematopoietic manifestations.</p><p>Most patients had lymphopenia of varying degrees that worsened during infections [<a href="#rid102">102</a>]. The CD4:CD8 T cell ratio was inversed. Proliferation to antigens and mitogens was impaired. Immunoglobulin levels were normal to increased (particularly IgG), although antibody titers to <em>Streptococcus pneumoniae</em> were low.</p><p class="headingAnchor" id="H201829553"><span class="h4">Other inborn errors of immunity</span><span class="headingEndMark"> — </span>Susceptibility to EBV, lymphoproliferative conditions, and lymphoma are the main presenting features of other IEI, including those due to defects in the following [<a href="#rid16">16,106,107</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>T cell-B cell costimulatory signaling (CD27 and CD70 deficiencies, OX40 deficiency, CD137 deficiency)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Regulatory T cells controlling pathways (lipopolysaccharide [LPS]-responsive vesicle trafficking, beach- and anchor-containing [LRBA] and cytotoxic T lymphocyte antigen 4 [CTLA4] deficiencies)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Antigen-receptor downstream signaling (gain-of-function in phosphatidylinositol 3-kinase [PI3K], signal transducer and activator of transcription 3 [STAT3], and loss-of-function of nuclear factor [NF]-kappa-B1 [NFKB], and caspase recruitment domain-containing protein 11 [CARD11] over-activities)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Lymphocyte epigenetic regulators (TET2 deficiency)</p><p></p><p class="headingAnchor" id="H2974550657"><span class="h3">Human herpesvirus-8 (HHV8)</span><span class="headingEndMark"> — </span>Besides EBV and HPV, five other viruses are well recognized to be oncogenic in humans [<a href="#rid108">108</a>]. Among them, only human herpesvirus-8 (HHV8) or Kaposi sarcoma-associated herpesvirus (KSHV) had been occasionally reported in malignant primary immunodeficient patients with interferon-gamma receptor 1 (IFNGR1), stromal interaction molecule 1 (STIM1), and OX40 deficiencies.</p><p class="headingAnchor" id="H1067686997"><span class="h3">Human papillomavirus</span><span class="headingEndMark"> — </span>Human papillomavirus (HPV) is also responsible for malignant transformation in some IEI disorders. Recurrent, severe recalcitrant HPV infections are associated with many forms of IEI, including EV, WHIM syndrome (warts, hypogammaglobulinemia, infections, and myelokathexis), MonoMAC syndrome (GATA2 deficiency), and DOCK8 deficiency [<a href="#rid109">109</a>]. Patients with these disorders may develop malignancies (eg, cervical cancers) in the setting of severe or refractory mucosal warts. (See  <a class="medical medical_review" href="/z/d/html/8031.html" rel="external">"Virology of human papillomavirus infections and the link to cancer"</a>.)</p><p>As an example, HPV infection is considered the main predisposing factor for skin cancers in patients with EV. Overexpression of HPV viral genes, especially <em>E6</em> and <em>E7</em> oncogenetic genes, contributes to the impaired zinc homeostasis due to mutations in either of the <em>EVER1</em> or <em>EVER2</em> genes. The expression of EVER proteins has been observed in T and B cells, NK cells, bone marrow myeloid cells, and dendritic cells, and it is suggested that <em>EVER</em> genes modulate the immune response against HPV [<a href="#rid94">94,110,111</a>].</p><p class="headingAnchor" id="H1067687009"><span class="h4">WHIM syndrome</span><span class="headingEndMark"> — </span>Warts, hypogammaglobulinemia, infections, and myelokathexis (WHIM) syndrome is a rare IEI disorder, with an autosomal dominant pattern of inheritance caused by mutations in the gene responsible for the encoding of chemokine receptor CXCR4 [<a href="#rid112">112</a>]. Susceptibility to HPV infection in WHIM patients is known to be associated with CXCR4 gain-of-function. Patients are particularly prone to HPV infection, resulting in numerous warts, condylomata acuminate, and subsequent severe papillomatosis and malignant transformation of the lesions [<a href="#rid113">113</a>]. Impairments in the number and function of dendritic cells have been reported, which may also contribute to increased susceptibility to HPV and several other viral infections, such as EBV, herpes zoster, and herpes simplex viruses [<a href="#rid1">1,113</a>]. (See  <a class="medical medical_review" href="/z/d/html/15509.html" rel="external">"Epidermodysplasia verruciformis", section on 'WHIM syndrome'</a>.)</p><p class="headingAnchor" id="H1067687021"><span class="h2">Iatrogenic</span><span class="headingEndMark"> — </span>Iatrogenic interventions are probably an uncommon cause of malignancy in IEI patients. However, diagnostic or therapeutic procedures may trigger malignant formation in IEI patients with predisposing conditions.</p><p class="headingAnchor" id="H1067687027"><span class="h3">Radiation</span><span class="headingEndMark"> — </span>Patients with AT and NBS are prone to genetic instability and malignant formation after exposure to radiation or radiomimetic agents. Radiosensitivity in these patients is explained by defects in DNA repair, which acts as the primary response to ionizing radiation in healthy individuals [<a href="#rid32">32,33</a>].</p><p>In patients with CVID, a dose-dependent radiosensitivity was demonstrated by in vitro irradiation of lymphocytes [<a href="#rid64">64</a>]. This finding seemed to be more prominent among patients with consanguineous parents, suggesting that genetic defects with an autosomal recessive of inheritance are responsible in this subgroup of CVID patients. However, since the underlying genetic defect is not identified in most CVID cases, the exact etiology of increased radiosensitivity in these patients remains unknown.</p><p class="headingAnchor" id="H1067687045"><span class="h3">Post-transplant lymphoproliferative disorders</span><span class="headingEndMark"> — </span>Post-transplant lymphoproliferative disorders (PTLDs) are lymphoid and/or plasmacytic proliferations that mostly develop during the first six months after allogeneic HCT. They are usually caused by EBV-driven increased cell survival of germinal center B cells due to iatrogenic suppression of cellular immunity. Although uncommon, PTLDs are a potentially fatal complication of transplantation, with a mortality rate of approximately 50 percent. In both IEI and non-IEI patients, receiving T cell-depleted bone marrow transplantation is strongly associated with a higher incidence of PTLD. (See  <a class="medical medical_review" href="/z/d/html/83230.html" rel="external">"Epidemiology, clinical manifestations, and diagnosis of post-transplant lymphoproliferative disorders"</a> and  <a class="medical medical_review" href="/z/d/html/7335.html" rel="external">"Treatment and prevention of post-transplant lymphoproliferative disorders"</a>.)</p><p>HCT is the only available curative therapy for severe forms of IEI, such as severe combined immunodeficiency, and without transplantation, patients usually do not survive beyond the first two years of life. In a large survey of IEI patients undergoing HCT, PTLD was the most prevalent post-transplantation malignancy, observed in 52 out of 2266 cases (2.3 percent), with a median onset of three months post-HCT [<a href="#rid114">114</a>]. Of these 52 cases, 40 died, mainly due to post-transplantation malignancy. Thus, PTLD carries a poor prognosis, although even for patients with IEI, the overall risk is relatively low [<a href="#rid114">114,115</a>].</p><p class="headingAnchor" id="H1403639346"><span class="h1">HALLMARKS OF CANCERS IN IEI</span><span class="headingEndMark"> — </span>A system of categorizing hallmarks of cancer was proposed to help dissect the complexity of the neoplastic disease. Patients with antibody deficiency, combined immunodeficiency, and immune dysregulation have the most diverse array of hallmarks , including avoiding immune destruction, genome instability, mutation, enabling replicative immortality, tumor-promoting inflammation, resisting cell death, sustaining proliferative signaling, evading growth suppressors, deregulating cellular energetics, inducing angiogenesis, and activating invasion and metastasis [<a href="#rid116">116</a>].</p><p class="headingAnchor" id="H956855603"><span class="h1">FEATURES OF MALIGNANCIES IN PID</span><span class="headingEndMark"> — </span>Cancer in patients with IEI is generally more likely to disseminate or be widespread at the time of diagnosis and therefore have a poorer prognosis [<a href="#rid1">1</a>]. Malignancy in patients with IEI has some characteristic features compared with malignancies in immunocompetent individuals, based largely on observations in non-Hodgkin lymphoma (NHL) and Hodgkin lymphoma [<a href="#rid117">117</a>].</p><p class="headingAnchor" id="H1067687255"><span class="h2">Non-Hodgkin lymphoma</span><span class="headingEndMark"> — </span>Patients with IEI are more likely to have non-Hodgkin lymphoma (NHL) with B cell origin, high histologic grades, and extranodal involvement, especially in the gastrointestinal tract or central nervous system [<a href="#rid11">11,14</a>]. In addition, NHL is more commonly detected in association with Epstein-Barr virus (EBV) infection in about 30 to 60 percent of cases, especially in B cell types [<a href="#rid12">12,14</a>]. As mentioned previously, patients with NHL and IEI are diagnosed at younger ages, and males are disproportionally affected. (See <a class="local">'Epidemiology and prevalence of cancer in IEI'</a> above.)</p><p class="headingAnchor" id="H1067687267"><span class="h2">Hodgkin lymphoma</span><span class="headingEndMark"> — </span>The prognosis for patients with IEI and Hodgkin lymphoma is not as good as that for immunocompetent patients. In a case-control study of 120 pediatric Hodgkin lymphoma patients consisting of 20 IEI cases with Hodgkin lymphoma and 100 immunocompetent individuals, the chance of achieving remission and five-year survival was lower in patients with IEI [<a href="#rid15">15</a>].</p><p class="headingAnchor" id="H1067687273"><span class="h1">MONITORING FOR MALIGNANCY</span><span class="headingEndMark"> — </span>Patients with IEI should undergo all age-appropriate cancer screening procedures periodically, as it is indicated for immunocompetent individuals. Evaluation of IEI patients with suspected lymphoma is the same as those with normal immune systems. Diagnostic tests useful for cancer screening include measurement of uric acid, lactic dehydrogenase, and erythrocyte sedimentation rate [<a href="#rid118">118,119</a>]. Patients with ataxia-telangiectasia (AT) and their female family members with heterozygous mutant <em>ATM</em> should be advised to start the screening for breast cancer at an earlier age. This age can be determined by considering the type of mutation in the <em>ATM</em> gene [<a href="#rid29">29</a>].</p><p>Reviews of screening for cancer in adults and children and discussions of the clinical presentations of lymphomas are found separately:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/6243.html" rel="external">"Overview of common presenting signs and symptoms of childhood cancer"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/4695.html" rel="external">"Clinical presentation and initial evaluation of non-Hodgkin lymphoma", section on 'Clinical presentation'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/4688.html" rel="external">"Clinical presentation and diagnosis of classic Hodgkin lymphoma in adults"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/13940.html" rel="external">"Overview of non-Hodgkin lymphoma in children and adolescents", section on 'Clinical presentation'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/6246.html" rel="external">"Overview of Hodgkin lymphoma in children and adolescents", section on 'Clinical presentation'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/4743.html" rel="external">"Clinical presentation and diagnosis of primary gastrointestinal lymphomas"</a>.)</p><p></p><p class="headingAnchor" id="H693552214"><span class="h1">PATIENT EDUCATION</span></p><p class="headingAnchor" id="H693552221"><span class="h2">Warning signs of cancer</span><span class="headingEndMark"> — </span>Warning signs of malignancies should be carefully explained to patients. Special attention should be given to signs of lymphoma, as the most prevalent malignancy among IEI patients, as well as other types of cancers that are more prevalent among specific IEI disorders. Patients should be advised to report all signs to their clinicians, even though some of these, such as weight loss, recurrent fever, soaking night sweats, easy bruising or bleeding, and prolonged tiredness, may be explained by their underlying IEI disorder. (See  <a class="medical medical_basics" href="/z/d/html/15492.html" rel="external">"Patient education: Lymphoma (The Basics)"</a>.)</p><p class="headingAnchor" id="H693552227"><span class="h2">What to avoid</span><span class="headingEndMark"> — </span>General recommendations for cancer prevention (eg, avoidance of sexually transmitted diseases, excessive alcohol, obesity, etc) should be discussed with patients. (See  <a class="medical medical_review" href="/z/d/html/6893.html" rel="external">"Overview of cancer prevention"</a>.)</p><p>Patients with specific disorders, including ataxia-telangiectasia, Nijmegen breakage syndrome, and common variable immunodeficiency, should be informed regarding their radiosensitivity, which may increase the risk of developing malignancy. These patients should consult their immunologist before agreeing to any diagnostic or therapeutic intervention involving radiation that is suggested by other clinicians. Clinicians should consider the risks and benefits of the intervention in the context of the underlying disorder, the necessity of the procedure, replacement with radiation-free technique alternative (eg, sonography and magnetic resonance imaging) and, when possible, in vitro analysis of the patient's radiosensitivity [<a href="#rid64">64</a>].</p><p>Patients with epidermodysplasia verruciformis should be informed regarding the necessity of stringent sun protection and avoidance of sun exposure. Regular physical examinations by a dermatologist are recommended for such patients. (See <a class="local">'Epidermodysplasia verruciformis'</a> above.)</p><p class="headingAnchor" id="H693552264"><span class="h2">Consanguinity</span><span class="headingEndMark"> — </span>A number of IEI disorders are inherited in an autosomal recessive pattern. It should be explained to individuals with autosomal recessive disorders and to their families that marriages between relatives increase the likelihood of other children being affected. This is especially important in countries where this practice is prevalent. (See  <a class="medical medical_review" href="/z/d/html/6893.html" rel="external">"Overview of cancer prevention"</a>.)</p><p class="headingAnchor" id="H1067687323"><span class="h1">TREATMENT CONSIDERATIONS</span><span class="headingEndMark"> — </span>Due to the rare and heterogeneous nature of IEI disorders, only a few studies evaluated specific protocols in the treatment of various types of malignancies in these patients.</p><p>Malignant cells in patients with IEI do not show an increased resistance to the standard therapeutic protocols [<a href="#rid1">1</a>]. However, management of cancer can be challenging in these individuals compared with immunocompetent patients, since they are more likely to develop widespread cancer requiring more aggressive cytotoxic therapies, which in turn, are more likely to cause life-threatening infections and end-organ damage in patients with IEI [<a href="#rid1">1</a>]. Thus, whenever possible, clinicians should attempt to customize the therapeutic management of cancers in IEI patients based on the condition of their immune system and complications of the underlying disorder [<a href="#rid120">120</a>].</p><p class="headingAnchor" id="H1067687329"><span class="h2">Chemotherapy</span><span class="headingEndMark"> — </span>Patients with IEI can receive the same chemotherapy protocols used in immunocompetent individuals with a similar malignancy. However, short chemotherapy protocols are preferable to longer regimens, with special attention to infection control and prophylaxis against <em>Pneumocystis jirovecii</em> pneumonia [<a href="#rid1">1,2</a>]. When possible, the chemotherapy regimen should be modified according to risk factors and tolerance of each individual. (See  <a class="medical medical_review" href="/z/d/html/1153.html" rel="external">"Prophylaxis of infection during chemotherapy-induced neutropenia in high-risk adults"</a> and  <a class="medical medical_review" href="/z/d/html/1393.html" rel="external">"Treatment and prevention of Pneumocystis pneumonia in patients without HIV"</a>.)</p><p>Examples of response to treatment and tolerance to chemotherapy in specific IEI disorders include the following:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>X-linked lymphoproliferative disease (XLP)</strong> – Although XLP patients with lymphomas may achieve remission after receiving standard chemotherapy without increased complications compared with immunocompetent individuals, relapse and development of another distinct lymphoma are also common [<a href="#rid121">121</a>]. XLP patients with lymphoma are usually treated using the standard chemotherapy regimen, which should be followed by allogeneic hematopoietic cell transplantation (HCT) as quickly as possible [<a href="#rid122">122</a>]. (See  <a class="medical medical_review" href="/z/d/html/3915.html" rel="external">"X-linked lymphoproliferative disease", section on 'Management'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Ataxia-telangiectasia (AT) and Nijmegen breakage syndrome (NBS)</strong> – Management of malignancies in AT and NBS patients is challenging due to poor tolerance of radiotherapy [<a href="#rid123">123</a>]. However, the exclusive use of chemotherapy without radiation seems to be efficient and well-tolerated in these patients. In a study on the outcome of polychemotherapy without radiotherapy in five AT and four NBS patients with non-Hodgkin lymphoma (NHL), only one patient died due to toxic complications. Two patients died as a result of relapse, one died of a second malignancy, and five patients remained at complete clinical remission after a median follow-up of five years [<a href="#rid124">124</a>]. Another group also reported good tolerance and response to treatment among AT patients with NHL, Hodgkin lymphoma, and acute lymphoblastic leukemia who received standard chemotherapy regimen as the sole treatment [<a href="#rid123">123,125,126</a>].</p><p></p><p class="headingAnchor" id="H1067687335"><span class="h2">Radiotherapy</span><span class="headingEndMark"> — </span>In patients with AT and NBS, radiotherapy should be limited to situations in which there is an absolute need for this treatment, and it should be administered at the lowest possible doses.</p><p>Radiotherapy and radiation-based diagnostic tests should be used very cautiously in patients with common variable immunodeficiency (CVID) due to reports of dose-dependent radiosensitivity of lymphocytes in vitro [<a href="#rid64">64,127,128</a>]. However, clinical trials evaluating the safety and efficacy of radiotherapy in patients with CVID and malignancies are unfortunately lacking.</p><p class="headingAnchor" id="H1067687354"><span class="h2">Antiviral agents</span><span class="headingEndMark"> — </span>Antiviral agents could theoretically decrease the risk of malignant transformation by reducing viral load, chronic inflammatory response, and persistent antigenic stimulation, although clinical studies have not been performed. <a class="drug drug_general" data-topicid="9335" href="/z/d/drug information/9335.html" rel="external">Acyclovir</a>, as the standard antiviral agent in the management of Epstein-Barr virus (EBV) infection, inhibits EBV DNA polymerase, which results in limiting the permissive (lytic) EBV infection. However, evidence regarding the role of the permissive phase of infection as a predisposing factor to malignancy is needed. (See  <a class="medical medical_review" href="/z/d/html/8283.html" rel="external">"Clinical manifestations and treatment of Epstein-Barr virus infection"</a>.)</p><p class="headingAnchor" id="H3118011924"><span class="h2">Helicobacter pylori infection eradication</span><span class="headingEndMark"> — </span><em>Helicobacter pylori </em>is implicated in the development of chronic gastritis and gastric atrophy, promoting carcinogenesis through intestinal metaplasia and dysplasia to carcinoma. Rates of gastric cancer may be decreasing in CVID patients with the more prevalent use of antibiotics that eliminate<em> H. pylori</em> [<a href="#rid68">68</a>].</p><p class="headingAnchor" id="H1067687366"><span class="h2">Rituximab</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">Rituximab</a> is an anti-CD20 monoclonal antibody that eliminates B cells and is used in the treatment of B cell lymphoma. EBV-induced malignant transformation among IEI patients is considered to be the result of uncontrolled expansion of EBV-infected B cells and a probable subsequent proliferation and activation of T cells. Thus, it is possible that rituximab may reduce the risk of EBV-induced lymphoma by eliminating EBV-infected B cells.</p><p><a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">Rituximab</a> has been used with apparent success in controlling acute EBV infection in a small number of patients with X-linked lymphoproliferative (XLP) disease [<a href="#rid129">129</a>]. In these patients, the number of B cells dropped to about 1 percent or less of the total number of circulating lymphocytes, and leukocyte-associated EBV DNA in patients' peripheral blood declined to the limits below the detection limit. The use of rituximab in XLP is described separately. (See  <a class="medical medical_review" href="/z/d/html/3915.html" rel="external">"X-linked lymphoproliferative disease", section on 'Treatment of acute EBV infection'</a>.)</p><p class="headingAnchor" id="H3183619228"><span class="h2">Other targeted therapies</span></p><p>The selective phosphatidylinositol 3-kinase (PI3K) inhibitors, which can be used in cases with activated PI3K mutations, have shown impressive efficacy and tolerability in patients with certain B cell cancers and are in phase III clinical trials [<a href="#rid130">130</a>]. Treatment with <a class="drug drug_general" data-topicid="10329" href="/z/d/drug information/10329.html" rel="external">sirolimus</a> (rapamycin), an mTOR inhibitor, can also partially restore NK cell cytotoxicity which is important in immune surveillance of these patients as well as ALPS cases [<a href="#rid131">131,132</a>] . </p><p>Monoclonal antibodies may replace traditional chemotherapy and its sometimes life-threatening side effects, or at least allow for reduced chemotherapy dose intensity, in patients with DNA repair defects characterized by a progressive decrease in T cell numbers [<a href="#rid133">133</a>]. However, monoclonal antibodies have their own adverse effects. Some are the consequence of off-target effects, such as the neurotoxicity reported after administration of <a class="drug drug_general" data-topicid="98582" href="/z/d/drug information/98582.html" rel="external">blinatumomab</a> (bi-specific T cell engager antibodies) [<a href="#rid96">96</a>]. (See  <a class="medical medical_review" href="/z/d/html/2825.html" rel="external">"Neurologic complications of cancer treatment with molecularly targeted and biologic agents", section on 'Bispecific T cell engagers'</a>.)</p><p class="headingAnchor" id="H1067687372"><span class="h2">Stem cell transplantation</span><span class="headingEndMark"> — </span>HCT is the only curative therapy available for a number of IEI disorders associated with higher malignancy rates, including severe combined immunodeficiency, XLP, Wiskott-Aldrich syndrome, X-linked hyperimmunoglobulin M syndrome, and dedicator of cytokinesis 8 (DOCK) deficiency [<a href="#rid134">134-136</a>]. However, even after HCT, some patients may remain at increased risk for malignancies. As an example, patients with DOCK8 deficiency remain predisposed to cancers because DOCK8 may play a tumor suppression role in nonhematopoietic tissues [<a href="#rid17">17</a>]. (See  <a class="medical medical_review" href="/z/d/html/3941.html" rel="external">"Hematopoietic cell transplantation for non-SCID inborn errors of immunity"</a> and  <a class="medical medical_review" href="/z/d/html/115988.html" rel="external">"Hematopoietic cell transplantation for severe combined immunodeficiencies"</a>.)</p><p class="headingAnchor" id="H1665971121"><span class="h2">Viral-specific T cell therapies</span><span class="headingEndMark"> — </span>Viral-specific T lymphocyte therapies (VSTs) involve infusions of cytotoxic T lymphocytes that have been engineered in vitro to target specific viruses. VST can be used to prevent or treat specific viral infections, or to treat virally-driven malignancies [<a href="#rid133">133</a>]. A review collated data from 18 studies in which 63 patients with IEI received VSTs to either prevent or treat viral infections, usually following HCT, with an overall response rate of 79 percent [<a href="#rid137">137</a>]. The most common diagnoses were SCID and hemophagocytic lymphohistiocytosis. The main virus targets were tumorigenic ones (CMV, EBV), although VSTs were also useful against adenovirus, BK virus, and human herpesvirus 6 (HHV6) with a low rate of side effects, including graft-versus-host disease and cytokine release syndrome. Production of VSTs currently requires a clean-room or good manufacturing practice facility and the regulatory infrastructure to support the quality of process, which is the main current challenge for this modality. </p><p class="headingAnchor" id="H956854488"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Risk of malignant disease in patients with IEI </strong>– The overall risk for developing cancer in patients with inborn errors of immunity (IEI), formerly called primary immunodeficiencies (PIDs), is estimated to range from 4 to 25 percent, which is less than twofold above that of the general population. As advances in the treatment of IEI have resulted in longer life expectancies, there has been a corresponding increase in diagnosed malignancies. The most common types of cancer in patients with IEI are non-Hodgkin lymphoma (NHL) and Hodgkin lymphoma, which together account for approximately 60 percent of malignancy cases. Patients with IEI develop lymphomas at somewhat younger ages compared with immunocompetent populations. The IEIs with the highest incidences of cancers are ataxia-telangiectasia and common variable immunodeficiency. (See <a class="local">'Epidemiology and prevalence of cancer in IEI'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Potential mechanisms</strong> – Several mechanisms have been suggested to contribute to the high susceptibility of distinct groups of IEI patients to specific types of malignancies. These include impaired genetic stability, genetic predisposition, immune dysregulation, impaired clearance of oncogenic viruses, and iatrogenic interventions  (<a class="graphic graphic_table graphicRef96198" href="/z/d/graphic/96198.html" rel="external">table 1</a>). (See <a class="local">'Mechanisms of increased susceptibility to malignancy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Features of malignancies in IEI</strong> – Cancers of all types in patients with IEI are more likely to disseminate or be widespread at the time of diagnosis. NHL in patients with IEI tends to be of B cell origin, have high histologic grades, be associated with Epstein-Barr virus infection, and involve extranodal tissues, especially the gastrointestinal tract and central nervous system. (See <a class="local">'Features of malignancies in PID'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Monitoring</strong> – Patients with IEI should undergo all age-appropriate cancer screening procedures periodically, as indicated for immunocompetent individuals. In addition to general measures to avoid developing cancer (eg, avoidance of sexually-transmitted diseases, excessive alcohol, obesity, etc), patients should be educated about the signs and symptoms of the specific types of cancer associated with their IEI, especially lymphoma. In cultures in which consanguinity is widespread, families with a member with IEI should be counseled to avoid marriages between relatives. (See <a class="local">'Monitoring for malignancy'</a> above and <a class="local">'Patient education'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment principles</strong> – Malignant cells in IEI patients do not show an increased resistance to the standard therapeutic protocols. However, patients with IEI are more likely to develop widespread cancer requiring more aggressive therapy, and the adverse effects of these treatments, such as infections and end-organ damage, are often poorly tolerated. Therefore, treatments should be chosen with the patient's underlying susceptibilities in mind and less toxic therapies preferred whenever possible. Monoclonal antibodies and virus-specific T cell therapies are expanding treatment options for this vulnerable population. (See <a class="local">'Treatment considerations'</a> above.)</p><p></p><p class="headingAnchor" id="H191867741"><span class="h1">ACKNOWLEDGMENTS</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Asghar Aghamohammadi, MD, PhD and Babak Mirminachi, MD, MPH, who contributed as authors to earlier versions of this topic review.</p><p>The UpToDate editorial staff also acknowledges E Richard Stiehm, MD, who contributed as a Section Editor to earlier versions of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Shapiro RS. Malignancies in the setting of primary immunodeficiency: Implications for hematologists/oncologists. Am J Hematol 2011; 86:48.</a></li><li><a class="nounderline abstract_t">Salavoura K, Kolialexi A, Tsangaris G, Mavrou A. Development of cancer in patients with primary immunodeficiencies. Anticancer Res 2008; 28:1263.</a></li><li><a class="nounderline abstract_t">Mortaz E, Tabarsi P, Mansouri D, et al. Cancers Related to Immunodeficiencies: Update and Perspectives. Front Immunol 2016; 7:365.</a></li><li><a class="nounderline abstract_t">Filipovich AH, Mathur A, Kamat D, Shapiro RS. Primary immunodeficiencies: genetic risk factors for lymphoma. Cancer Res 1992; 52:5465s.</a></li><li><a class="nounderline abstract_t">Mayor PC, Eng KH, Singel KL, et al. Cancer in primary immunodeficiency diseases: Cancer incidence in the United States Immune Deficiency Network Registry. J Allergy Clin Immunol 2018; 141:1028.</a></li><li><a class="nounderline abstract_t">Vajdic CM, Mao L, van Leeuwen MT, et al. Are antibody deficiency disorders associated with a narrower range of cancers than other forms of immunodeficiency? Blood 2010; 116:1228.</a></li><li><a class="nounderline abstract_t">Jonkman-Berk BM, van den Berg JM, Ten Berge IJ, et al. Primary immunodeficiencies in the Netherlands: national patient data demonstrate the increased risk of malignancy. Clin Immunol 2015; 156:154.</a></li><li><a class="nounderline abstract_t">Thaventhiran JED, Lango Allen H, Burren OS, et al. Whole-genome sequencing of a sporadic primary immunodeficiency cohort. Nature 2020; 583:90.</a></li><li><a class="nounderline abstract_t">Riaz IB, Faridi W, Patnaik MM, Abraham RS. A Systematic Review on Predisposition to Lymphoid (B and T cell) Neoplasias in Patients With Primary Immunodeficiencies and Immune Dysregulatory Disorders (Inborn Errors of Immunity). Front Immunol 2019; 10:777.</a></li><li><a class="nounderline abstract_t">Kebudi R, Kiykim A, Sahin MK. Primary Immunodeficiency and Cancer in Children; A Review of the Literature. Curr Pediatr Rev 2019; 15:245.</a></li><li><a class="nounderline abstract_t">Cohen JM, Sebire NJ, Harvey J, et al. Successful treatment of lymphoproliferative disease complicating primary immunodeficiency/immunodysregulatory disorders with reduced-intensity allogeneic stem-cell transplantation. Blood 2007; 110:2209.</a></li><li><a class="nounderline abstract_t">Seidemann K, Tiemann M, Henze G, et al. Therapy for non-Hodgkin lymphoma in children with primary immunodeficiency: analysis of 19 patients from the BFM trials. Med Pediatr Oncol 1999; 33:536.</a></li><li class="breakAll">Gross TSB. Lymphoproliferative disorders and malignancies related to immunodeficiencies. In: Principles and Practice of Pediatric Oncology, 6th ed, Pizzo PA, Poplack DG (Eds), Lippincott Williams &amp; Wilkins, Philadelphia, PA 2006. p.748.</li><li><a class="nounderline abstract_t">Kiykim A, Eker N, Surekli O, et al. Malignancy and lymphoid proliferation in primary immune deficiencies; hard to define, hard to treat. Pediatr Blood Cancer 2020; 67:e28091.</a></li><li><a class="nounderline abstract_t">Robison LL, Stoker V, Frizzera G, et al. Hodgkin's disease in pediatric patients with naturally occurring immunodeficiency. Am J Pediatr Hematol Oncol 1987; 9:189.</a></li><li><a class="nounderline abstract_t">Hauck F, Voss R, Urban C, Seidel MG. Intrinsic and extrinsic causes of malignancies in patients with primary immunodeficiency disorders. J Allergy Clin Immunol 2018; 141:59.</a></li><li><a class="nounderline abstract_t">Rezaei N, Hedayat M, Aghamohammadi A, Nichols KE. Primary immunodeficiency diseases associated with increased susceptibility to viral infections and malignancies. J Allergy Clin Immunol 2011; 127:1329.</a></li><li><a class="nounderline abstract_t">Knittel G, Rehkämper T, Nieper P, et al. DNA damage pathways and B-cell lymphomagenesis. Curr Opin Hematol 2018; 25:315.</a></li><li><a class="nounderline abstract_t">McGrath-Morrow SA, Gower WA, Rothblum-Oviatt C, et al. Evaluation and management of pulmonary disease in ataxia-telangiectasia. Pediatr Pulmonol 2010; 45:847.</a></li><li><a class="nounderline abstract_t">Nowak-Wegrzyn A, Crawford TO, Winkelstein JA, et al. Immunodeficiency and infections in ataxia-telangiectasia. J Pediatr 2004; 144:505.</a></li><li><a class="nounderline abstract_t">Suarez F, Mahlaoui N, Canioni D, et al. Incidence, presentation, and prognosis of malignancies in ataxia-telangiectasia: a report from the French national registry of primary immune deficiencies. J Clin Oncol 2015; 33:202.</a></li><li><a class="nounderline abstract_t">Jette NR, Kumar M, Radhamani S, et al. ATM-Deficient Cancers Provide New Opportunities for Precision Oncology. Cancers (Basel) 2020; 12.</a></li><li><a class="nounderline abstract_t">Amirifar P, Ranjouri MR, Yazdani R, et al. Ataxia-telangiectasia: A review of clinical features and molecular pathology. Pediatr Allergy Immunol 2019; 30:277.</a></li><li><a class="nounderline abstract_t">Khanna KK, Keating KE, Kozlov S, et al. ATM associates with and phosphorylates p53: mapping the region of interaction. Nat Genet 1998; 20:398.</a></li><li><a class="nounderline abstract_t">Cortez D, Wang Y, Qin J, Elledge SJ. Requirement of ATM-dependent phosphorylation of brca1 in the DNA damage response to double-strand breaks. Science 1999; 286:1162.</a></li><li><a class="nounderline abstract_t">Chen J. Ataxia telangiectasia-related protein is involved in the phosphorylation of BRCA1 following deoxyribonucleic acid damage. Cancer Res 2000; 60:5037.</a></li><li><a class="nounderline abstract_t">Swift M, Reitnauer PJ, Morrell D, Chase CL. Breast and other cancers in families with ataxia-telangiectasia. N Engl J Med 1987; 316:1289.</a></li><li><a class="nounderline abstract_t">Jerzak KJ, Mancuso T, Eisen A. Ataxia-telangiectasia gene (ATM) mutation heterozygosity in breast cancer: a narrative review. Curr Oncol 2018; 25:e176.</a></li><li><a class="nounderline abstract_t">van Os NJ, Roeleveld N, Weemaes CM, et al. Health risks for ataxia-telangiectasia mutated heterozygotes: a systematic review, meta-analysis and evidence-based guideline. Clin Genet 2016; 90:105.</a></li><li><a class="nounderline abstract_t">Chrzanowska KH, Gregorek H, Dembowska-Bagińska B, et al. Nijmegen breakage syndrome (NBS). Orphanet J Rare Dis 2012; 7:13.</a></li><li><a class="nounderline abstract_t">Demuth I, Frappart PO, Hildebrand G, et al. An inducible null mutant murine model of Nijmegen breakage syndrome proves the essential function of NBS1 in chromosomal stability and cell viability. Hum Mol Genet 2004; 13:2385.</a></li><li><a class="nounderline abstract_t">Gatei M, Young D, Cerosaletti KM, et al. ATM-dependent phosphorylation of nibrin in response to radiation exposure. Nat Genet 2000; 25:115.</a></li><li><a class="nounderline abstract_t">Wu X, Ranganathan V, Weisman DS, et al. ATM phosphorylation of Nijmegen breakage syndrome protein is required in a DNA damage response. Nature 2000; 405:477.</a></li><li><a class="nounderline abstract_t">Buscemi G, Savio C, Zannini L, et al. Chk2 activation dependence on Nbs1 after DNA damage. Mol Cell Biol 2001; 21:5214.</a></li><li><a class="nounderline abstract_t">Falck J, Petrini JH, Williams BR, et al. The DNA damage-dependent intra-S phase checkpoint is regulated by parallel pathways. Nat Genet 2002; 30:290.</a></li><li><a class="nounderline abstract_t">Uziel T, Lerenthal Y, Moyal L, et al. Requirement of the MRN complex for ATM activation by DNA damage. EMBO J 2003; 22:5612.</a></li><li><a class="nounderline abstract_t">Thrasher AJ, Burns SO. WASP: a key immunological multitasker. Nat Rev Immunol 2010; 10:182.</a></li><li><a class="nounderline abstract_t">Burger B, Itin PH. Epidermodysplasia verruciformis. Curr Probl Dermatol 2014; 45:123.</a></li><li><a class="nounderline abstract_t">Sullivan KE, Mullen CA, Blaese RM, Winkelstein JA. A multiinstitutional survey of the Wiskott-Aldrich syndrome. J Pediatr 1994; 125:876.</a></li><li><a class="nounderline abstract_t">Rivers E, Worth A, Thrasher AJ, Burns SO. How I manage patients with Wiskott Aldrich syndrome. Br J Haematol 2019; 185:647.</a></li><li><a class="nounderline abstract_t">Imai K, Morio T, Zhu Y, et al. Clinical course of patients with WASP gene mutations. Blood 2004; 103:456.</a></li><li class="breakAll">Thrasher AJ. New insights into the biology of Wiskott-Aldrich syndrome (WAS). Hematology Am Soc Hematol Educ Program 2009; 132.</li><li><a class="nounderline abstract_t">Bosticardo M, Marangoni F, Aiuti A, et al. Recent advances in understanding the pathophysiology of Wiskott-Aldrich syndrome. Blood 2009; 113:6288.</a></li><li><a class="nounderline abstract_t">Ochs HD, Thrasher AJ. The Wiskott-Aldrich syndrome. J Allergy Clin Immunol 2006; 117:725.</a></li><li><a class="nounderline abstract_t">Picard C, Mellouli F, Duprez R, et al. Kaposi's sarcoma in a child with Wiskott-Aldrich syndrome. Eur J Pediatr 2006; 165:453.</a></li><li><a class="nounderline abstract_t">Meropol NJ, Hicks D, Brooks JJ, et al. Coincident Kaposi sarcoma and T-cell lymphoma in a patient with the Wiskott-Aldrich syndrome. Am J Hematol 1992; 40:126.</a></li><li><a class="nounderline abstract_t">de Oliveira WR, Festa Neto C, Rady PL, Tyring SK. Clinical aspects of epidermodysplasia verruciformis. J Eur Acad Dermatol Venereol 2003; 17:394.</a></li><li><a class="nounderline abstract_t">Ramoz N, Rueda LA, Bouadjar B, et al. Mutations in two adjacent novel genes are associated with epidermodysplasia verruciformis. Nat Genet 2002; 32:579.</a></li><li><a class="nounderline abstract_t">Vohra S, Sharma NL, Shanker V, et al. Autosomal dominant epidermodysplasia verruciformis: a clinicotherapeutic experience in two cases. Indian J Dermatol Venereol Leprol 2010; 76:557.</a></li><li><a class="nounderline abstract_t">Jackson S, Harwood C, Thomas M, et al. Role of Bak in UV-induced apoptosis in skin cancer and abrogation by HPV E6 proteins. Genes Dev 2000; 14:3065.</a></li><li><a class="nounderline abstract_t">Iftner T, Elbel M, Schopp B, et al. Interference of papillomavirus E6 protein with single-strand break repair by interaction with XRCC1. EMBO J 2002; 21:4741.</a></li><li><a class="nounderline abstract_t">Forslund O, Lindelöf B, Hradil E, et al. High prevalence of cutaneous human papillomavirus DNA on the top of skin tumors but not in "Stripped" biopsies from the same tumors. J Invest Dermatol 2004; 123:388.</a></li><li><a class="nounderline abstract_t">Orth G. Human papillomaviruses associated with epidermodysplasia verruciformis in non-melanoma skin cancers: guilty or innocent? J Invest Dermatol 2005; 125:xii.</a></li><li><a class="nounderline abstract_t">Welte K, Zeidler C, Dale DC. Severe congenital neutropenia. Semin Hematol 2006; 43:189.</a></li><li><a class="nounderline abstract_t">Germeshausen M, Ballmaier M, Welte K. Incidence of CSF3R mutations in severe congenital neutropenia and relevance for leukemogenesis: Results of a long-term survey. Blood 2007; 109:93.</a></li><li><a class="nounderline abstract_t">Makaryan V, Zeidler C, Bolyard AA, et al. The diversity of mutations and clinical outcomes for ELANE-associated neutropenia. Curr Opin Hematol 2015; 22:3.</a></li><li><a class="nounderline abstract_t">Picard C, Bobby Gaspar H, Al-Herz W, et al. International Union of Immunological Societies: 2017 Primary Immunodeficiency Diseases Committee Report on Inborn Errors of Immunity. J Clin Immunol 2018; 38:96.</a></li><li><a class="nounderline abstract_t">Zhang Q, Davis JC, Lamborn IT, et al. Combined immunodeficiency associated with DOCK8 mutations. N Engl J Med 2009; 361:2046.</a></li><li><a class="nounderline abstract_t">Su HC. Dedicator of cytokinesis 8 (DOCK8) deficiency. Curr Opin Allergy Clin Immunol 2010; 10:515.</a></li><li><a class="nounderline abstract_t">Engelhardt KR, McGhee S, Winkler S, et al. Large deletions and point mutations involving the dedicator of cytokinesis 8 (DOCK8) in the autosomal-recessive form of hyper-IgE syndrome. J Allergy Clin Immunol 2009; 124:1289.</a></li><li><a class="nounderline abstract_t">Saelee P, Wongkham S, Puapairoj A, et al. Novel PNLIPRP3 and DOCK8 gene expression and prognostic implications of DNA loss on chromosome 10q25.3 in hepatocellular carcinoma. Asian Pac J Cancer Prev 2009; 10:501.</a></li><li><a class="nounderline abstract_t">Takahashi K, Kohno T, Ajima R, et al. Homozygous deletion and reduced expression of the DOCK8 gene in human lung cancer. Int J Oncol 2006; 28:321.</a></li><li><a class="nounderline abstract_t">Nagayama K, Kohno T, Sato M, et al. Homozygous deletion scanning of the lung cancer genome at a 100-kb resolution. Genes Chromosomes Cancer 2007; 46:1000.</a></li><li><a class="nounderline abstract_t">Aghamohammadi A, Moin M, Kouhi A, et al. Chromosomal radiosensitivity in patients with common variable immunodeficiency. Immunobiology 2008; 213:447.</a></li><li><a class="nounderline abstract_t">Cunningham-Rundles C, Bodian C. Common variable immunodeficiency: clinical and immunological features of 248 patients. Clin Immunol 1999; 92:34.</a></li><li><a class="nounderline abstract_t">Gangemi S, Allegra A, Musolino C. Lymphoproliferative disease and cancer among patients with common variable immunodeficiency. Leuk Res 2015; 39:389.</a></li><li><a class="nounderline abstract_t">Tak Manesh A, Azizi G, Heydari A, et al. Epidemiology and pathophysiology of malignancy in common variable immunodeficiency? Allergol Immunopathol (Madr) 2017; 45:602.</a></li><li><a class="nounderline abstract_t">Resnick ES, Moshier EL, Godbold JH, Cunningham-Rundles C. Morbidity and mortality in common variable immune deficiency over 4 decades. Blood 2012; 119:1650.</a></li><li><a class="nounderline abstract_t">Wehr C, Gennery AR, Lindemans C, et al. Multicenter experience in hematopoietic stem cell transplantation for serious complications of common variable immunodeficiency. J Allergy Clin Immunol 2015; 135:988.</a></li><li><a class="nounderline abstract_t">Zullo A, Romiti A, Rinaldi V, et al. Gastric pathology in patients with common variable immunodeficiency. Gut 1999; 45:77.</a></li><li><a class="nounderline abstract_t">Ludvigsson JF, Neovius M, Ye W, Hammarström L. IgA deficiency and risk of cancer: a population-based matched cohort study. J Clin Immunol 2015; 35:182.</a></li><li><a class="nounderline abstract_t">Price S, Shaw PA, Seitz A, et al. Natural history of autoimmune lymphoproliferative syndrome associated with FAS gene mutations. Blood 2014; 123:1989.</a></li><li><a class="nounderline abstract_t">Rosa DD, Pasqualotto AC, Denning DW. Chronic mucocutaneous candidiasis and oesophageal cancer. Med Mycol 2008; 46:85.</a></li><li><a class="nounderline abstract_t">Shouval DS, Ebens CL, Murchie R, et al. Large B-Cell Lymphoma in an Adolescent Patient With Interleukin-10 Receptor Deficiency and History of Infantile Inflammatory Bowel Disease. J Pediatr Gastroenterol Nutr 2016; 63:e15.</a></li><li><a class="nounderline abstract_t">Martin D, Gutkind JS. Human tumor-associated viruses and new insights into the molecular mechanisms of cancer. Oncogene 2008; 27 Suppl 2:S31.</a></li><li><a class="nounderline abstract_t">Philip M, Rowley DA, Schreiber H. Inflammation as a tumor promoter in cancer induction. Semin Cancer Biol 2004; 14:433.</a></li><li><a class="nounderline abstract_t">Bartkova J, Horejsí Z, Koed K, et al. DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. Nature 2005; 434:864.</a></li><li><a class="nounderline abstract_t">Sayos J, Wu C, Morra M, et al. The X-linked lymphoproliferative-disease gene product SAP regulates signals induced through the co-receptor SLAM. Nature 1998; 395:462.</a></li><li><a class="nounderline abstract_t">Shinozaki K, Kanegane H, Matsukura H, et al. Activation-dependent T cell expression of the X-linked lymphoproliferative disease gene product SLAM-associated protein and its assessment for patient detection. Int Immunol 2002; 14:1215.</a></li><li><a class="nounderline abstract_t">Parolini S, Bottino C, Falco M, et al. X-linked lymphoproliferative disease. 2B4 molecules displaying inhibitory rather than activating function are responsible for the inability of natural killer cells to kill Epstein-Barr virus-infected cells. J Exp Med 2000; 192:337.</a></li><li><a class="nounderline abstract_t">Sumegi J, Huang D, Lanyi A, et al. Correlation of mutations of the SH2D1A gene and epstein-barr virus infection with clinical phenotype and outcome in X-linked lymphoproliferative disease. Blood 2000; 96:3118.</a></li><li><a class="nounderline abstract_t">Morra M, Howie D, Grande MS, et al. X-linked lymphoproliferative disease: a progressive immunodeficiency. Annu Rev Immunol 2001; 19:657.</a></li><li><a class="nounderline abstract_t">Schwartzberg PL, Mueller KL, Qi H, Cannons JL. SLAM receptors and SAP influence lymphocyte interactions, development and function. Nat Rev Immunol 2009; 9:39.</a></li><li><a class="nounderline abstract_t">Pasquier B, Yin L, Fondanèche MC, et al. Defective NKT cell development in mice and humans lacking the adapter SAP, the X-linked lymphoproliferative syndrome gene product. J Exp Med 2005; 201:695.</a></li><li><a class="nounderline abstract_t">Nagy N, Matskova L, Kis LL, et al. The proapoptotic function of SAP provides a clue to the clinical picture of X-linked lymphoproliferative disease. Proc Natl Acad Sci U S A 2009; 106:11966.</a></li><li><a class="nounderline abstract_t">Renukaradhya GJ, Khan MA, Vieira M, et al. Type I NKT cells protect (and type II NKT cells suppress) the host's innate antitumor immune response to a B-cell lymphoma. Blood 2008; 111:5637.</a></li><li><a class="nounderline abstract_t">Bassiri H, Janice Yeo WC, Rothman J, et al. X-linked lymphoproliferative disease (XLP): a model of impaired anti-viral, anti-tumor and humoral immune responses. Immunol Res 2008; 42:145.</a></li><li><a class="nounderline abstract_t">Felices M, Berg LJ. The Tec kinases Itk and Rlk regulate NKT cell maturation, cytokine production, and survival. J Immunol 2008; 180:3007.</a></li><li><a class="nounderline abstract_t">Huck K, Feyen O, Niehues T, et al. Girls homozygous for an IL-2-inducible T cell kinase mutation that leads to protein deficiency develop fatal EBV-associated lymphoproliferation. J Clin Invest 2009; 119:1350.</a></li><li><a class="nounderline abstract_t">Miller AT, Berg LJ. Defective Fas ligand expression and activation-induced cell death in the absence of IL-2-inducible T cell kinase. J Immunol 2002; 168:2163.</a></li><li class="breakAll">Linka RM, Huck K, Krux F, et al. Germline mutations within the IL2-inducible T cell kinase impede T cell differentiation or survival, cause protein destabilisation, loss of membrane recruitment and lead to severe EBV lymphoproliferation. American Society of Hematology Meeting. Orlando, FL 2010.</li><li><a class="nounderline abstract_t">Khurana D, Arneson LN, Schoon RA, et al. Differential regulation of human NK cell-mediated cytotoxicity by the tyrosine kinase Itk. J Immunol 2007; 178:3575.</a></li><li><a class="nounderline abstract_t">Orth G. Genetics of epidermodysplasia verruciformis: Insights into host defense against papillomaviruses. Semin Immunol 2006; 18:362.</a></li><li><a class="nounderline abstract_t">Su AI, Wiltshire T, Batalov S, et al. A gene atlas of the mouse and human protein-encoding transcriptomes. Proc Natl Acad Sci U S A 2004; 101:6062.</a></li><li><a class="nounderline abstract_t">Hayward AR, Levy J, Facchetti F, et al. Cholangiopathy and tumors of the pancreas, liver, and biliary tree in boys with X-linked immunodeficiency with hyper-IgM. J Immunol 1997; 158:977.</a></li><li><a class="nounderline abstract_t">Baleydier F, Bernard F, Ansari M. The Possibilities of Immunotherapy for Children with Primary Immunodeficiencies Associated with Cancers. Biomolecules 2020; 10.</a></li><li><a class="nounderline abstract_t">Hughes CR, Guasti L, Meimaridou E, et al. MCM4 mutation causes adrenal failure, short stature, and natural killer cell deficiency in humans. J Clin Invest 2012; 122:814.</a></li><li><a class="nounderline abstract_t">Orange JS. Natural killer cell deficiency. J Allergy Clin Immunol 2013; 132:515.</a></li><li><a class="nounderline abstract_t">Revy P, Buck D, le Deist F, de Villartay JP. The repair of DNA damages/modifications during the maturation of the immune system: lessons from human primary immunodeficiency disorders and animal models. Adv Immunol 2005; 87:237.</a></li><li><a class="nounderline abstract_t">Moshous D, Martin E, Carpentier W, et al. Whole-exome sequencing identifies Coronin-1A deficiency in 3 siblings with immunodeficiency and EBV-associated B-cell lymphoproliferation. J Allergy Clin Immunol 2013; 131:1594.</a></li><li><a class="nounderline abstract_t">Stepensky P, Weintraub M, Yanir A, et al. IL-2-inducible T-cell kinase deficiency: clinical presentation and therapeutic approach. Haematologica 2011; 96:472.</a></li><li><a class="nounderline abstract_t">Martin E, Palmic N, Sanquer S, et al. CTP synthase 1 deficiency in humans reveals its central role in lymphocyte proliferation. Nature 2014; 510:288.</a></li><li><a class="nounderline abstract_t">Li FY, Chaigne-Delalande B, Su H, et al. XMEN disease: a new primary immunodeficiency affecting Mg2+ regulation of immunity against Epstein-Barr virus. Blood 2014; 123:2148.</a></li><li><a class="nounderline abstract_t">Li FY, Chaigne-Delalande B, Kanellopoulou C, et al. Second messenger role for Mg2+ revealed by human T-cell immunodeficiency. Nature 2011; 475:471.</a></li><li><a class="nounderline abstract_t">Chaigne-Delalande B, Li FY, O'Connor GM, et al. Mg2+ regulates cytotoxic functions of NK and CD8 T cells in chronic EBV infection through NKG2D. Science 2013; 341:186.</a></li><li><a class="nounderline abstract_t">Somekh I, Thian M, Medgyesi D, et al. CD137 deficiency causes immune dysregulation with predisposition to lymphomagenesis. Blood 2019; 134:1510.</a></li><li><a class="nounderline abstract_t">Stremenova Spegarova J, Lawless D, Mohamad SMB, et al. Germline TET2 loss of function causes childhood immunodeficiency and lymphoma. Blood 2020; 136:1055.</a></li><li><a class="nounderline abstract_t">Béziat V, Jouanguy E. Human inborn errors of immunity to oncogenic viruses. Curr Opin Immunol 2021; 72:277.</a></li><li><a class="nounderline abstract_t">Leiding JW, Holland SM. Warts and all: human papillomavirus in primary immunodeficiencies. J Allergy Clin Immunol 2012; 130:1030.</a></li><li><a class="nounderline abstract_t">Lazarczyk M, Cassonnet P, Pons C, et al. The EVER proteins as a natural barrier against papillomaviruses: a new insight into the pathogenesis of human papillomavirus infections. Microbiol Mol Biol Rev 2009; 73:348.</a></li><li><a class="nounderline abstract_t">Lazarczyk M, Pons C, Mendoza JA, et al. Regulation of cellular zinc balance as a potential mechanism of EVER-mediated protection against pathogenesis by cutaneous oncogenic human papillomaviruses. J Exp Med 2008; 205:35.</a></li><li><a class="nounderline abstract_t">Kawai T, Malech HL. WHIM syndrome: congenital immune deficiency disease. Curr Opin Hematol 2009; 16:20.</a></li><li><a class="nounderline abstract_t">Pablos JL, Amara A, Bouloc A, et al. Stromal-cell derived factor is expressed by dendritic cells and endothelium in human skin. Am J Pathol 1999; 155:1577.</a></li><li><a class="nounderline abstract_t">Kamani NR, Kumar S, Hassebroek A, et al. Malignancies after hematopoietic cell transplantation for primary immune deficiencies: a report from the Center for International Blood and Marrow Transplant Research. Biol Blood Marrow Transplant 2011; 17:1783.</a></li><li><a class="nounderline abstract_t">Curtis RE, Travis LB, Rowlings PA, et al. Risk of lymphoproliferative disorders after bone marrow transplantation: a multi-institutional study. Blood 1999; 94:2208.</a></li><li><a class="nounderline abstract_t">Abolhassani H, Wang Y, Hammarström L, Pan-Hammarström Q. Hallmarks of Cancers: Primary Antibody Deficiency Versus Other Inborn Errors of Immunity. Front Immunol 2021; 12:720025.</a></li><li><a class="nounderline abstract_t">Levine AM. Lymphoma complicating immunodeficiency disorders. Ann Oncol 1994; 5 Suppl 2:29.</a></li><li><a class="nounderline abstract_t">Woolf SH, Harris R. The harms of screening: new attention to an old concern. JAMA 2012; 307:565.</a></li><li><a class="nounderline abstract_t">Welch HG, Black WC. Overdiagnosis in cancer. J Natl Cancer Inst 2010; 102:605.</a></li><li><a class="nounderline abstract_t">Tran H, Nourse J, Hall S, et al. Immunodeficiency-associated lymphomas. Blood Rev 2008; 22:261.</a></li><li><a class="nounderline abstract_t">Booth C, Gilmour KC, Veys P, et al. X-linked lymphoproliferative disease due to SAP/SH2D1A deficiency: a multicenter study on the manifestations, management and outcome of the disease. Blood 2011; 117:53.</a></li><li class="breakAll">Sumegi J, Johnson J, Filipovich A, et al. Lymphoproliferative disease, X-linked. In: GeneReviews, Pagon RA, Adam MP, Bird TD, et al. (Eds), University of Washington, Seattle 2009.</li><li><a class="nounderline abstract_t">Sandoval C, Swift M. Treatment of lymphoid malignancies in patients with ataxia-telangiectasia. Med Pediatr Oncol 1998; 31:491.</a></li><li><a class="nounderline abstract_t">Seidemann K, Henze G, Beck JD, et al. Non-Hodgkin's lymphoma in pediatric patients with chromosomal breakage syndromes (AT and NBS): experience from the BFM trials. Ann Oncol 2000; 11 Suppl 1:141.</a></li><li><a class="nounderline abstract_t">Sandoval C, Swift M. Hodgkin disease in ataxia-telangiectasia patients with poor outcomes. Med Pediatr Oncol 2003; 40:162.</a></li><li><a class="nounderline abstract_t">Dembowska-Baginska B, Perek D, Brozyna A, et al. Non-Hodgkin lymphoma (NHL) in children with Nijmegen Breakage syndrome (NBS). Pediatr Blood Cancer 2009; 52:186.</a></li><li><a class="nounderline abstract_t">Vorechovský I, Scott D, Haeney MR, Webster DA. Chromosomal radiosensitivity in common variable immune deficiency. Mutat Res 1993; 290:255.</a></li><li><a class="nounderline abstract_t">Serra G, Milito C, Mitrevski M, et al. Lung MRI as a possible alternative to CT scan for patients with primary immune deficiencies and increased radiosensitivity. Chest 2011; 140:1581.</a></li><li><a class="nounderline abstract_t">Milone MC, Tsai DE, Hodinka RL, et al. Treatment of primary Epstein-Barr virus infection in patients with X-linked lymphoproliferative disease using B-cell-directed therapy. Blood 2005; 105:994.</a></li><li><a class="nounderline abstract_t">Conley ME, Fruman DA. Genetics. Can cancer drugs treat immunodeficiency? Science 2013; 342:814.</a></li><li><a class="nounderline abstract_t">Ruiz-García R, Vargas-Hernández A, Chinn IK, et al. Mutations in PI3K110δ cause impaired natural killer cell function partially rescued by rapamycin treatment. J Allergy Clin Immunol 2018; 142:605.</a></li><li><a class="nounderline abstract_t">Durandy A, Kracker S. Increased activation of PI3 kinase-δ predisposes to B-cell lymphoma. Blood 2020; 135:638.</a></li><li><a class="nounderline abstract_t">Rubinstein JD, Burns K, Absalon M, et al. EBV-directed viral-specific T-lymphocyte therapy for the treatment of EBV-driven lymphoma in two patients with primary immunodeficiency and DNA repair defects. Pediatr Blood Cancer 2020; 67:e28126.</a></li><li><a class="nounderline abstract_t">Griffith LM, Cowan MJ, Notarangelo LD, et al. Improving cellular therapy for primary immune deficiency diseases: recognition, diagnosis, and management. J Allergy Clin Immunol 2009; 124:1152.</a></li><li><a class="nounderline abstract_t">Prunotto G, Offor UT, Samarasinghe S, et al. HSCT provides effective treatment for lymphoproliferative disorders in children with primary immunodeficiency. J Allergy Clin Immunol 2020; 146:447.</a></li><li><a class="nounderline abstract_t">Chan AY, Leiding JW, Liu X, et al. Hematopoietic Cell Transplantation in Patients With Primary Immune Regulatory Disorders (PIRD): A Primary Immune Deficiency Treatment Consortium (PIDTC) Survey. Front Immunol 2020; 11:239.</a></li><li><a class="nounderline abstract_t">Keller MD, Bollard CM. Virus-specific T-cell therapies for patients with primary immune deficiency. Blood 2020; 135:620.</a></li></ol></div><div id="topicVersionRevision">Topic 95906 Version 20.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21120868" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Malignancies in the setting of primary immunodeficiency: Implications for hematologists/oncologists.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18505064" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Development of cancer in patients with primary immunodeficiencies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27703456" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Cancers Related to Immunodeficiencies: Update and Perspectives.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1327508" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Primary immunodeficiencies: genetic risk factors for lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28606585" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Cancer in primary immunodeficiency diseases: Cancer incidence in the United States Immune Deficiency Network Registry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20466855" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Are antibody deficiency disorders associated with a narrower range of cancers than other forms of immunodeficiency?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25451158" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Primary immunodeficiencies in the Netherlands: national patient data demonstrate the increased risk of malignancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32499645" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Whole-genome sequencing of a sporadic primary immunodeficiency cohort.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31057537" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : A Systematic Review on Predisposition to Lymphoid (B and T cell) Neoplasias in Patients With Primary Immunodeficiencies and Immune Dysregulatory Disorders (Inborn Errors of Immunity).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31530267" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Primary Immunodeficiency and Cancer in Children; A Review of the Literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17502458" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Successful treatment of lymphoproliferative disease complicating primary immunodeficiency/immunodysregulatory disorders with reduced-intensity allogeneic stem-cell transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10573576" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Therapy for non-Hodgkin lymphoma in children with primary immunodeficiency: analysis of 19 patients from the BFM trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10573576" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Therapy for non-Hodgkin lymphoma in children with primary immunodeficiency: analysis of 19 patients from the BFM trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31736244" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Malignancy and lymphoid proliferation in primary immune deficiencies; hard to define, hard to treat.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3592132" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Hodgkin's disease in pediatric patients with naturally occurring immunodeficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28669558" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Intrinsic and extrinsic causes of malignancies in patients with primary immunodeficiency disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21514636" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Primary immunodeficiency diseases associated with increased susceptibility to viral infections and malignancies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29702521" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : DNA damage pathways and B-cell lymphomagenesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20583220" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Evaluation and management of pulmonary disease in ataxia-telangiectasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15069401" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Immunodeficiency and infections in ataxia-telangiectasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25488969" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Incidence, presentation, and prognosis of malignancies in ataxia-telangiectasia: a report from the French national registry of primary immune deficiencies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32183301" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : ATM-Deficient Cancers Provide New Opportunities for Precision Oncology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30685876" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Ataxia-telangiectasia: A review of clinical features and molecular pathology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9843217" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : ATM associates with and phosphorylates p53: mapping the region of interaction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10550055" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Requirement of ATM-dependent phosphorylation of brca1 in the DNA damage response to double-strand breaks.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11016625" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Ataxia telangiectasia-related protein is involved in the phosphorylation of BRCA1 following deoxyribonucleic acid damage.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3574400" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Breast and other cancers in families with ataxia-telangiectasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29719442" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Ataxia-telangiectasia gene (ATM) mutation heterozygosity in breast cancer: a narrative review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26662178" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Health risks for ataxia-telangiectasia mutated heterozygotes: a systematic review, meta-analysis and evidence-based guideline.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22373003" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Nijmegen breakage syndrome (NBS).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15333589" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : An inducible null mutant murine model of Nijmegen breakage syndrome proves the essential function of NBS1 in chromosomal stability and cell viability.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10802669" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : ATM-dependent phosphorylation of nibrin in response to radiation exposure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10839545" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : ATM phosphorylation of Nijmegen breakage syndrome protein is required in a DNA damage response.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11438675" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Chk2 activation dependence on Nbs1 after DNA damage.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11850621" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : The DNA damage-dependent intra-S phase checkpoint is regulated by parallel pathways.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14532133" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Requirement of the MRN complex for ATM activation by DNA damage.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20182458" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : WASP: a key immunological multitasker.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24643182" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Epidermodysplasia verruciformis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7996359" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : A multiinstitutional survey of the Wiskott-Aldrich syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30864154" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : How I manage patients with Wiskott Aldrich syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12969986" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Clinical course of patients with WASP gene mutations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12969986" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Clinical course of patients with WASP gene mutations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19351959" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Recent advances in understanding the pathophysiology of Wiskott-Aldrich syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16630926" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : The Wiskott-Aldrich syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16602009" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Kaposi's sarcoma in a child with Wiskott-Aldrich syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1316718" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Coincident Kaposi sarcoma and T-cell lymphoma in a patient with the Wiskott-Aldrich syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12834447" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Clinical aspects of epidermodysplasia verruciformis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12426567" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Mutations in two adjacent novel genes are associated with epidermodysplasia verruciformis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20826999" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Autosomal dominant epidermodysplasia verruciformis: a clinicotherapeutic experience in two cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11114894" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Role of Bak in UV-induced apoptosis in skin cancer and abrogation by HPV E6 proteins.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12198176" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Interference of papillomavirus E6 protein with single-strand break repair by interaction with XRCC1.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15245440" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : High prevalence of cutaneous human papillomavirus DNA on the top of skin tumors but not in "Stripped" biopsies from the same tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15982294" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Human papillomaviruses associated with epidermodysplasia verruciformis in non-melanoma skin cancers: guilty or innocent?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16822461" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Severe congenital neutropenia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16985178" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Incidence of CSF3R mutations in severe congenital neutropenia and relevance for leukemogenesis: Results of a long-term survey.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25427142" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : The diversity of mutations and clinical outcomes for ELANE-associated neutropenia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29226302" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : International Union of Immunological Societies: 2017 Primary Immunodeficiency Diseases Committee Report on Inborn Errors of Immunity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19776401" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Combined immunodeficiency associated with DOCK8 mutations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20864884" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Dedicator of cytokinesis 8 (DOCK8) deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20004785" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Large deletions and point mutations involving the dedicator of cytokinesis 8 (DOCK8) in the autosomal-recessive form of hyper-IgE syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19640199" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Novel PNLIPRP3 and DOCK8 gene expression and prognostic implications of DNA loss on chromosome 10q25.3 in hepatocellular carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16391785" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Homozygous deletion and reduced expression of the DOCK8 gene in human lung cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17674361" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Homozygous deletion scanning of the lung cancer genome at a 100-kb resolution.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18472053" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Chromosomal radiosensitivity in patients with common variable immunodeficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10413651" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Common variable immunodeficiency: clinical and immunological features of 248 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25711943" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Lymphoproliferative disease and cancer among patients with common variable immunodeficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28411962" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Epidemiology and pathophysiology of malignancy in common variable immunodeficiency?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22180439" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Morbidity and mortality in common variable immune deficiency over 4 decades.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25595268" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Multicenter experience in hematopoietic stem cell transplantation for serious complications of common variable immunodeficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10369708" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Gastric pathology in patients with common variable immunodeficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25589342" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : IgA deficiency and risk of cancer: a population-based matched cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24398331" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Natural history of autoimmune lymphoproliferative syndrome associated with FAS gene mutations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17852718" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Chronic mucocutaneous candidiasis and oesophageal cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27336593" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Large B-Cell Lymphoma in an Adolescent Patient With Interleukin-10 Receptor Deficiency and History of Infantile Inflammatory Bowel Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19956178" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Human tumor-associated viruses and new insights into the molecular mechanisms of cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15489136" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Inflammation as a tumor promoter in cancer induction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15829956" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9774102" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : The X-linked lymphoproliferative-disease gene product SAP regulates signals induced through the co-receptor SLAM.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12356686" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Activation-dependent T cell expression of the X-linked lymphoproliferative disease gene product SLAM-associated protein and its assessment for patient detection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10934222" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : X-linked lymphoproliferative disease. 2B4 molecules displaying inhibitory rather than activating function are responsible for the inability of natural killer cells to kill Epstein-Barr virus-infected cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11049992" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Correlation of mutations of the SH2D1A gene and epstein-barr virus infection with clinical phenotype and outcome in X-linked lymphoproliferative disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11244050" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : X-linked lymphoproliferative disease: a progressive immunodeficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19079134" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : SLAM receptors and SAP influence lymphocyte interactions, development and function.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15738056" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Defective NKT cell development in mice and humans lacking the adapter SAP, the X-linked lymphoproliferative syndrome gene product.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19570996" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : The proapoptotic function of SAP provides a clue to the clinical picture of X-linked lymphoproliferative disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18417738" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Type I NKT cells protect (and type II NKT cells suppress) the host's innate antitumor immune response to a B-cell lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18815745" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : X-linked lymphoproliferative disease (XLP): a model of impaired anti-viral, anti-tumor and humoral immune responses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18292523" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : The Tec kinases Itk and Rlk regulate NKT cell maturation, cytokine production, and survival.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19425169" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Girls homozygous for an IL-2-inducible T cell kinase mutation that leads to protein deficiency develop fatal EBV-associated lymphoproliferation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11859102" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Defective Fas ligand expression and activation-induced cell death in the absence of IL-2-inducible T cell kinase.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11859102" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Defective Fas ligand expression and activation-induced cell death in the absence of IL-2-inducible T cell kinase.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17339454" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Differential regulation of human NK cell-mediated cytotoxicity by the tyrosine kinase Itk.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17011789" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Genetics of epidermodysplasia verruciformis: Insights into host defense against papillomaviruses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15075390" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : A gene atlas of the mouse and human protein-encoding transcriptomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8993019" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Cholangiopathy and tumors of the pancreas, liver, and biliary tree in boys with X-linked immunodeficiency with hyper-IgM.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32731356" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : The Possibilities of Immunotherapy for Children with Primary Immunodeficiencies Associated with Cancers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22354170" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : MCM4 mutation causes adrenal failure, short stature, and natural killer cell deficiency in humans.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23993353" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Natural killer cell deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16102576" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : The repair of DNA damages/modifications during the maturation of the immune system: lessons from human primary immunodeficiency disorders and animal models.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23522482" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Whole-exome sequencing identifies Coronin-1A deficiency in 3 siblings with immunodeficiency and EBV-associated B-cell lymphoproliferation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21109689" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : IL-2-inducible T-cell kinase deficiency: clinical presentation and therapeutic approach.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24870241" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : CTP synthase 1 deficiency in humans reveals its central role in lymphocyte proliferation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24550228" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : XMEN disease: a new primary immunodeficiency affecting Mg2+ regulation of immunity against Epstein-Barr virus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21796205" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Second messenger role for Mg2+ revealed by human T-cell immunodeficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23846901" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Mg2+ regulates cytotoxic functions of NK and CD8 T cells in chronic EBV infection through NKG2D.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31501153" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : CD137 deficiency causes immune dysregulation with predisposition to lymphomagenesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32518946" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Germline TET2 loss of function causes childhood immunodeficiency and lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34364035" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : Human inborn errors of immunity to oncogenic viruses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23036745" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : Warts and all: human papillomavirus in primary immunodeficiencies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19487731" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : The EVER proteins as a natural barrier against papillomaviruses: a new insight into the pathogenesis of human papillomavirus infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18158319" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : Regulation of cellular zinc balance as a potential mechanism of EVER-mediated protection against pathogenesis by cutaneous oncogenic human papillomaviruses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19057201" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : WHIM syndrome: congenital immune deficiency disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10550315" id="rid112" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>113 : Stromal-cell derived factor is expressed by dendritic cells and endothelium in human skin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21658461" id="rid113" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>114 : Malignancies after hematopoietic cell transplantation for primary immune deficiencies: a report from the Center for International Blood and Marrow Transplant Research.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10498590" id="rid114" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>115 : Risk of lymphoproliferative disorders after bone marrow transplantation: a multi-institutional study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34484227" id="rid115" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>116 : Hallmarks of Cancers: Primary Antibody Deficiency Versus Other Inborn Errors of Immunity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8204517" id="rid116" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>117 : Lymphoma complicating immunodeficiency disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22318274" id="rid117" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>118 : The harms of screening: new attention to an old concern.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20413742" id="rid118" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>119 : Overdiagnosis in cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18456377" id="rid119" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>120 : Immunodeficiency-associated lymphomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20926771" id="rid120" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>121 : X-linked lymphoproliferative disease due to SAP/SH2D1A deficiency: a multicenter study on the manifestations, management and outcome of the disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20926771" id="rid121" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>122 : X-linked lymphoproliferative disease due to SAP/SH2D1A deficiency: a multicenter study on the manifestations, management and outcome of the disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9835901" id="rid122" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>123 : Treatment of lymphoid malignancies in patients with ataxia-telangiectasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10707797" id="rid123" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>124 : Non-Hodgkin's lymphoma in pediatric patients with chromosomal breakage syndromes (AT and NBS): experience from the BFM trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12518345" id="rid124" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>125 : Hodgkin disease in ataxia-telangiectasia patients with poor outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18937313" id="rid125" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>126 : Non-Hodgkin lymphoma (NHL) in children with Nijmegen Breakage syndrome (NBS).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7694117" id="rid126" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>127 : Chromosomal radiosensitivity in common variable immune deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21622550" id="rid127" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>128 : Lung MRI as a possible alternative to CT scan for patients with primary immune deficiencies and increased radiosensitivity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15494422" id="rid128" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>129 : Treatment of primary Epstein-Barr virus infection in patients with X-linked lymphoproliferative disease using B-cell-directed therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24233715" id="rid129" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>130 : Genetics. Can cancer drugs treat immunodeficiency?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29330011" id="rid130" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>131 : Mutations in PI3K110δcause impaired natural killer cell function partially rescued by rapamycin treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31942637" id="rid131" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>132 : Increased activation of PI3 kinase-δpredisposes to B-cell lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31850668" id="rid132" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>133 : EBV-directed viral-specific T-lymphocyte therapy for the treatment of EBV-driven lymphoma in two patients with primary immunodeficiency and DNA repair defects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20004776" id="rid133" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>134 : Improving cellular therapy for primary immune deficiency diseases: recognition, diagnosis, and management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32371070" id="rid134" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>135 : HSCT provides effective treatment for lymphoproliferative disorders in children with primary immunodeficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32153572" id="rid135" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>136 : Hematopoietic Cell Transplantation in Patients With Primary Immune Regulatory Disorders (PIRD): A Primary Immune Deficiency Treatment Consortium (PIDTC) Survey.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31942610" id="rid136" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>137 : Virus-specific T-cell therapies for patients with primary immune deficiency.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
